

# CITATION REPORT

List of articles citing

## A rule of threerfor fragment-based lead discovery?

DOI: 10.1016/s1359-6446(03)02831-9  
Drug Discovery Today, 2003, 8, 876-7.

**Source:** <https://exaly.com/paper-pdf/34995646/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1130	. <b>2004</b> ,		28
1129	Dynamic Covalent Chemistry in Fragment-Based Drug Discovery. <b>2004</b> , 1-9		
1128	Fragment-based lead discovery. <b>2004</b> , 3, 660-72		618
1127	Pursuing the leadlikeness concept in pharmaceutical research. <b>2004</b> , 8, 255-63		459
1126	Lead- and drug-like compounds: the rule-of-five revolution. <b>2004</b> , 1, 337-41		2365
1125	Fragment-based drug discovery. <b>2004</b> , 47, 3463-82		533
1124	Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. <b>2004</b> , 44, 2157-66		131
1123	Target-based compound library design and synthesis. <b>2004</b> , 3, 48-50		1
1122	Navigation in Chemical Space: Ligand-Based Design of Focused Compound Libraries. <b>2004</b> , 341-376		14
1121	Solution nuclear magnetic resonance spectroscopy techniques for probing intermolecular interactions. <b>2005</b> , 12, 961-71		72
1120	In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors. <b>2005</b> , 15, 5207-10		69
1119	A new school for screening. <b>2005</b> , 23, 184-6		16
1118	Fragment-based lead discovery: leads by design. <i>Drug Discovery Today</i> , <b>2005</b> , 10, 987-92	8.8	294
1117	The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography. <b>2005</b> , 6, 506-12		36
1116	Discovery of Thrombin Inhibitor Fragments from Chemical Microarray Screening. <b>2005</b> , 2, 590-594		19
1115	Fragment-based lead discovery using X-ray crystallography. <b>2005</b> , 48, 403-13		379
1114	Chapter 11 Filtering in Drug Discovery. <b>2005</b> , 1, 155-168		29

1113	High-throughput physicochemical and in vitro ADMET screening. <b>2005</b> , 3, 83-100	14
1112	Fragment screening: an introduction. <b>2006</b> , 2, 430-46	123
1111	Fragment screening by biochemical assay. <b>2006</b> , 1, 225-36	39
1110	Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. <b>2006</b> , 49, 1346-55	121
1109	The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. <b>2006</b> , 49, 2969-78	117
1108	. <b>2006</b> ,	56
1107	Chapter 11 Recent Advances in Design of Small-Molecule Ligands to Target Protein-Protein Interactions. <b>2006</b> , 197-219	1
1106	Birch bark research and development. <b>2006</b> , 23, 919-42	248
1105	Leadlikeness and structural diversity of synthetic screening libraries. <b>2006</b> , 10, 377-88	54
1104	Virtual ligand screening: strategies, perspectives and limitations. <i>Drug Discovery Today</i> , <b>2006</b> , 11, 580-948.8	543
1103	Hit discovery and hit-to-lead approaches. <i>Drug Discovery Today</i> , <b>2006</b> , 11, 741-8	8.8 180
1102	Shape Signatures: speeding up computer aided drug discovery. <i>Drug Discovery Today</i> , <b>2006</b> , 11, 895-904 8.8	26
1101	Oncology exploration: charting cancer medicinal chemistry space. <i>Drug Discovery Today</i> , <b>2006</b> , 11, 149-58.8	41
1100	Combining docking and molecular dynamic simulations in drug design. <b>2006</b> , 26, 531-68	453
1099	Pyramid: An Integrated Platform for Fragment-based Drug Discovery. <b>2006</b> , 193-214	10
1098	Fragment-based Lead Discovery and Optimization Using X-Ray Crystallography, Computational Chemistry, and High-throughput Organic Synthesis. <b>2006</b> , 215-248	26
1097	Cheminformatics Approaches to Fragment-based Lead Discovery. <b>2006</b> , 89-111	1
1096	Receptor-based computational screening of compound databases: the main docking-scoring engines. <b>2006</b> , 7, 369-93	40

1095	Structure-Based Drug Discovery. <b>2007</b> ,	23
1094	Ligand efficiency indices for effective drug discovery. <b>2007</b> , 2, 469-88	211
1093	An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. <b>2007</b> , 7, 1600-29	114
1092	Pharmacophore modeling in drug discovery and development: an overview. <b>2007</b> , 3, 187-97	93
1091	Fragment based drug discovery using fluorescence correlation: spectroscopy techniques: challenges and solutions. <b>2007</b> , 7, 1582-91	58
1090	Free resources to assist structure-based virtual ligand screening experiments. <b>2007</b> , 8, 381-411	91
1089	SPR-based fragment screening: advantages and applications. <b>2007</b> , 7, 1630-42	175
1088	Substructural Analysis in Drug Discovery. <b>2007</b> , 3, 59-67	8
1087	Scaffold-Based Drug Discovery. <b>2007</b> , 129-153	6
1086	New Applications for Structure-Based Drug Design. <b>2007</b> , 775-806	0
1085	Properties Guiding Drug- and Lead-Likeness. <b>2007</b> , 439-461	6
1084	Crystal structure of calf spleen purine nucleoside phosphorylase complexed to a novel purine analogue. <b>2007</b> , 581, 5082-6	9
1083	A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors. <b>2007</b> , 2, 329-36	47
1082	WOMBAT and WOMBAT-PK: Bioactivity Databases for Lead and Drug Discovery. 760-786	58
1081	On sampling of fragment space. <b>2007</b> , 50, 3214-21	32
1080	Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. <b>2007</b> , 47, 342-53	318
1079	Fragment-based drug discovery using the SHAPES method. <b>2007</b> , 2, 1555-66	13
1078	Application of fragment screening by X-ray crystallography to beta-secretase. <b>2007</b> , 50, 1116-23	139

1077	Design of inhibitors of the MurF enzyme of <i>Streptococcus pneumoniae</i> using docking, 3D-QSAR, and de Novo design. <b>2007</b> , 47, 1839-46		19
1076	Designing active template molecules by combining computational de novo design and human chemist's expertise. <b>2007</b> , 50, 1925-32		16
1075	NMR screening applied to the fragment-based generation of inhibitors of creatine kinase exploiting a new interaction proximate to the ATP binding site. <b>2007</b> , 50, 1865-75		18
1074	An Introduction To Chemoinformatics. <b>2007</b> ,		191
1073	Combinatorial Synthetic Design: The Balance of Novelty and Familiarity. <b>2007</b> , 91-111		
1072	Lead Discovery and the Concepts of Complexity and Lead-Likeness in the Evolution of Drug Candidates. <b>2007</b> , 435-458		
1071	Fragment-Based Approaches. <b>2007</b> , 939-957		1
1070	. <b>2007</b> ,		6
1069	Protein Crystallography in Drug Discovery. <b>2007</b> , 875-900		3
1068	GPCR targeted library design: novel dopamine D3 receptor ligands. <b>2007</b> , 2, 1000-5		11
1067	Fragment-based approaches to enzyme inhibition. <b>2007</b> , 18, 489-96		88
1066	The interdependence between screening methods and screening libraries. <b>2007</b> , 11, 244-51		54
1065	Empirical rules facilitate the search for binding sites on protein surfaces. <b>2007</b> , 25, 671-9		6
1064	Identification of novel fragment compounds targeted against the pY pocket of v-Src SH2 by computational and NMR screening and thermodynamic evaluation. <b>2007</b> , 67, 981-90		29
1063	Scaffold composition and biological relevance of screening libraries. <b>2007</b> , 3, 442-6		148
1062	Integration of fragment screening and library design. <i>Drug Discovery Today</i> , <b>2007</b> , 12, 1032-9	8.8	133
1061	A sorcerer's apprentice and The Rule of Five: from rule-of-thumb to commandment and beyond. <i>Drug Discovery Today</i> , <b>2007</b> , 12, 995-7	8.8	39
1060	Optimizing fragment and scaffold docking by use of molecular interaction fingerprints. <b>2007</b> , 47, 195-207		302

1059	Chapter 16:Discovery and Extrapolation of Fragment Structures towards Drug Design. <b>2007</b> , 293-318	1
1058	Fragment Screening: An Introduction. <b>2007</b> , 142-172	1
1057	A screening study of ChirBase molecular database to explore the expanded chiral pool derived from the application of chiral chromatography. <b>2008</b> , 46, 839-47	27
1056	Alternative measures of lipophilicity: from octanol-water partitioning to IAM retention. <b>2008</b> , 97, 2984-3004	104
1055	Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. <b>2008</b> , 3, 435-44	251
1054	Fragment-based activity space: smaller is better. <b>2008</b> , 12, 260-8	50
1053	Lead-Likeness and Drug-Likeness. <b>2008</b> , 244-254	7
1052	Developing a drug-like natural product library. <b>2008</b> , 71, 464-8	154
1051	Perspectives on NMR in drug discovery: a technique comes of age. <b>2008</b> , 7, 738-45	318
1050	Fragment-based drug discovery using rational design. <b>2007</b> , 169-85	11
1049	Designing a Fragment Process to Fit Your Needs. 15-37	2
1048	Hit Generation. <b>2008</b> , 218-279	1
1047	Identification and selection of "privileged fragments" suitable for primary screening. <b>2008</b> , 48, 2129-39	21
1046	Protein Crystallography and Drug Discovery. <b>2008</b> , 605-634	1
1045	Fragment-based approach to drug lead discovery: overview and advances in various techniques. <b>2008</b> , 9, 217-27	45
1044	Virtual screening and its integration with modern drug design technologies. <b>2008</b> , 15, 37-46	152
1043	Introduction to Fragment-Based Drug Discovery. 1-13	2
1042	Assembling a Fragment Library. 39-62	4

1041	Target-Immobilized NMR Screening: Validation and Extension to Membrane Proteins. 135-157		1
1040	. 2008,		21
1039	Lead-like Compounds. 2008, 242-III		
1038	Structural biology and anticancer drug design. 2008, 91-106		1
1037	Bibliography. 374-439		
1036	. 2009,		1
1035	NMR Spectroscopy in Fragment Based Drug Design. 2009, 125-139		1
1034	Fragment-based screening using surface plasmon resonance technology. 2009, 14, 337-49		95
1033	Recent advances in computer-aided drug design. 2009, 10, 579-91		164
1032	Practical aspects of the SAMPL challenge: providing an extensive experimental data set for the modeling community. 2009, 14, 1245-50		16
1031	Fragment library screening and lead characterization using SPR biosensors. 2009, 9, 1725-35		64
1030	Beyond the Model. 2009, 5, 139-144		
1029	From fragment screening to potent binders: strategies for fragment-to-lead evolution. 2009, 9, 956-61		12
1028	The role of medical structural genomics in discovering new drugs for infectious diseases. 2009, 5, e1000530		29
1027	Physicochemical property space distribution among human metabolites, drugs and toxins. 2009, 10 Suppl 15, S10		43
1026	Docking, virtual high throughput screening and in silico fragment-based drug design. 2009, 13, 238-48		103
1025	Two 'Golden Ratio' indices in fragment-based drug discovery. <i>Drug Discovery Today</i> , 2009, 14, 321-8	8.8	49
1024	'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries. <i>Drug Discovery Today</i> , 2009, 14, 31-40	8.8	103

1023	From fragment to clinical candidate--a historical perspective. <i>Drug Discovery Today</i> , <b>2009</b> , 14, 668-75	8.8	186
1022	On-chip fragment-based approach for discovery of high-affinity bivalent inhibitors. <b>2009</b> , 10, 838-43		9
1021	Design of compound libraries for fragment screening. <b>2009</b> , 23, 513-25		61
1020	Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors. <b>2009</b> , 23, 555-69		8
1019	Virtual fragment screening: an exploration of various docking and scoring protocols for fragments using Glide. <b>2009</b> , 23, 527-39		67
1018	The multiple roles of computational chemistry in fragment-based drug design. <b>2009</b> , 23, 459-73		44
1017	Fragment-based drug discovery. <b>2009</b> , 23, 453-8		35
1016	Emergent strategies for inverse molecular design. <b>2009</b> , 52, 1769-1776		9
1015	Direct optical detection in fragment-based screening. <b>2009</b> , 393, 1557-62		27
1014	The rise of fragment-based drug discovery. <b>2009</b> , 1, 187-92		503
1013	The influence of lead discovery strategies on the properties of drug candidates. <b>2009</b> , 8, 203-12		466
1012	CREDO: a protein-ligand interaction database for drug discovery. <b>2009</b> , 73, 157-67		64
1011	In silico screening for non-nucleoside HIV-1 reverse transcriptase inhibitors using physicochemical filters and high-throughput docking followed by in vitro evaluation. <b>2009</b> , 74, 258-65		21
1010	A road less traveled by: exploring a decade of Ellman chemistry. <b>2009</b> , 17, 1088-93		3
1009	Ruthenium complexes endowed with potent anti-Trypanosoma cruzi activity: Synthesis, biological characterization and structure-activity relationships. <b>2009</b> , 17, 5038-43		34
1008	Substituted 1,4-benzoxazepines, 1,5-benzoxazocines, and N- and S-variants. <b>2009</b> , 11, 5494-6		39
1007	Computational fragment-based approach at PDB scale by protein local similarity. <b>2009</b> , 49, 280-94		38
1006	Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design. <b>2009</b> , 48, 1-29		32



1005	Fragment-Based Drug Discovery in Academia: Experiences From a Tuberculosis Programme. <b>2009</b> , 21-36	3
1004	Integrative Risk Assessment. <b>2009</b> , 41-67	1
1003	Cheminformatic analysis of combinatorial libraries, drugs, natural products, and molecular libraries small molecule repository. <b>2009</b> , 49, 1010-24	131
1002	From Molecules to Medicines. <b>2009</b> ,	
1001	Overview of Hit to Lead: The Medicinal Chemist's Role from HTS Retest to Lead Optimization Hand Off. <b>2009</b> , 1-24	3
1000	970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. <b>2009</b> , 131, 8732-3	396
999	Bibliography. <b>2009</b> , 1-241	1
998	Advances in fragment-based drug discovery platforms. <b>2009</b> , 4, 1125-44	25
997	Modeling kinetics of subcellular disposition of chemicals. <b>2009</b> , 109, 1793-899	59
996	Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. <b>2009</b> , 52, 4694-715	103
995	A novel in silico approach to drug discovery via computational intelligence. <b>2009</b> , 49, 1105-21	25
994	Start small and stay small. Minimizing attrition in the clinic with a focus on CNS therapeutics. <b>2009</b> , 9, 1688-704	6
993	Fragment-based discovery of inhibitors of protein kinase B. <b>2009</b> , 9, 1705-17	10
992	Target immobilization and NMR screening of fragments in early drug discovery. <b>2009</b> , 9, 1736-45	13
991	Hit triage using efficiency indices after screening of compound libraries in drug discovery. <b>2009</b> , 9, 1718-24	14
990	[Fragment-based drug discovery: concept and aim]. <b>2010</b> , 130, 315-23	3
989	Fragment-Based Drug Design: Considerations for Good ADME Properties. <b>2010</b> , 417-485	
988	Cheminformatics. <b>2010</b> , 1	

987	Computational methods and software in computer-aided combinatorial library design. <b>2010</b> , 80, 2541-2571		0
986	Methods for combinatorial and parallel library design. <b>2011</b> , 672, 387-434		4
985	Some Trends in Chem(o)informatics. <b>2011</b> , 672, 1-37		15
984	Using protein-ligand docking to assess the chemical tractability of inhibiting a protein target. <b>2010</b> , 16, 1833-43		12
983	Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. <i>Drug Discovery Today</i> , <b>2010</b> , 15, 804-11	8.8	84
982	Thermodynamics guided lead discovery and optimization. <i>Drug Discovery Today</i> , <b>2010</b> , 15, 919-32	8.8	111
981	Fragmenting the S100B-p53 interaction: combined virtual/biophysical screening approaches to identify ligands. <b>2010</b> , 5, 428-35		19
980	Development of specific "drug-like property" rules for carboxylate-containing oral drug candidates. <b>2010</b> , 5, 2102-13		29
979	Fragment-Based Lead Discovery. <b>2010</b> , 105-139		3
978	A Fragment-Based In Situ Combinatorial Approach To Identify High-Affinity Ligands for Unknown Binding Sites. <b>2010</b> , 122, 5857-5861		7
977	A fragment-based in situ combinatorial approach to identify high-affinity ligands for unknown binding sites. <b>2010</b> , 49, 5721-5		43
976	Novel chiral pyrrolidinone scaffolds derived from threonine with antibacterial activity. <b>2010</b> , 21, 1758-1770		19
975	Algorithms for the automated selection of fragment-like molecules using single-point surface plasmon resonance measurements. <b>2010</b> , 402, 179-84		7
974	Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. <b>2010</b> , 17, 46-56		85
973	Application of fragment-based drug discovery to membrane proteins: identification of ligands of the integral membrane enzyme DsbB. <b>2010</b> , 17, 881-91		57
972	In-crystal chemical ligation for lead compound generation. <b>2010</b> , 43, 1329-1337		6
971	Fragment-based discovery of novel thymidylate synthase leads by NMR screening and group epitope mapping. <b>2010</b> , 76, 218-33		11
970	. <b>2010</b> ,		25

969	High-Throughput Methods of Chemical Synthesis Applied to the Preparation of Inhibitors of Protein-Protein Interactions. <b>2010</b> , 155-209	
968	. <b>2010</b> ,	2
967	Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-Drug Resistant HIV. <b>2010</b> , 443-463	
966	Fragment-based structure-guided drug discovery: strategy, process, and lessons from human protein kinases. 30-40	1
965	NMR in fragment-based drug discovery. 41-58	2
964	Fragment-based screening by biochemical assays: Systematic feasibility studies with trypsin and MMP12. <b>2010</b> , 15, 1029-41	34
963	Combinatorial Chemistry and Multiple Parallel Synthesis. <b>2010</b> , 275-368	1
962	Tutorial on Drug Development for Central Nervous System. <b>2010</b> , 2, 9.1-9.5	
961	Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors. <b>2010</b> , 431, 51-61	35
960	Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. <b>2010</b> , 6, 322-9	361
959	Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery. <b>2010</b> , 17, 1769-94	36
958	QSAR in the pharmaceutical research setting: QSAR models for broad, large problems. <b>2010</b> , 10, 619-37	45
957	Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors. <b>2010</b> , 53, 942-50	93
956	The T1R2/T1R3 sweet receptor and TRPM5 ion channel taste targets with therapeutic potential. <b>2010</b> , 91, 151-208	16
955	ADMET In Vitro Profiling: Utility and Applications in Lead Discovery. <b>2010</b> , 47-72	
954	Ligand specificity in fragment-based drug design. <b>2010</b> , 53, 5256-66	44
953	In silico docking and scoring of fragments. <b>2010</b> , 7, e147-202	16
952	Ligand efficiency as a guide in fragment hit selection and optimization. <b>2010</b> , 7, e147-202	121

951	Fragments: past, present and future. <b>2010</b> , 7, e147-202	38
950	Surface Plasmon Resonance biosensor analysis as a useful tool in FBDD. <b>2010</b> , 7, e181-e187	24
949	In Silico ADME/Tox Predictions. <b>2010</b> , 29-124	4
948	Structural studies of pterin-based inhibitors of dihydropteroate synthase. <b>2010</b> , 53, 166-77	62
947	Are there differences between launched drugs, clinical candidates, and commercially available compounds?. <b>2010</b> , 50, 815-21	16
946	A searchable map of PubChem. <b>2010</b> , 50, 1924-34	53
945	Chemical fragments that hydrogen bond to Asp, Glu, Arg, and His side chains in protein binding sites. <b>2010</b> , 53, 3086-94	27
944	Compound Collection Enhancement and Paradigms for High-Throughput Screening [an Update]. <b>2010</b> , 45, 409-428	12
943	Discovery of 4-[(2S)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. <b>2010</b> , 53, 573-85	52
942	Virtual fragment docking by Glide: a validation study on 190 protein-fragment complexes. <b>2010</b> , 50, 1165-72	75
941	Chemical space as a source for new drugs. <b>2010</b> , 1, 30	200
940	Virtual Screening with AutoDock: Theory and Practice. <b>2010</b> , 5, 597-607	326
939	Fragment library design: efficiently hunting drugs in chemical space. <b>2010</b> , 7, e147-202	30
938	Fragment-based deconstruction of Bcl-xL inhibitors. <b>2010</b> , 53, 2577-88	56
937	In silico fragment-based drug design. <b>2010</b> , 5, 1047-65	19
936	Computational analysis of structure-activity relationships. <b>2010</b> , 49, 113-60	14
935	Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. <b>2010</b> , 53, 951-65	110
934	Design of a high fragment efficiency library by molecular graph theory. <b>2010</b> , 1, 499-503	13

933	Overview on the Rule of Five. <b>2010</b> , Chapter 9, Unit 9.12	55
932	Fragment screening against the thiamine pyrophosphate riboswitchthiM. <b>2011</b> , 2, 157-165	41
931	Online parallel fragment screening and rapid hit exploration for nicotinic acetylcholine receptors. <b>2011</b> , 2, 590	4
930	Discovery of halopyridines as quiescent affinity labels: inactivation of dimethylarginine dimethylaminohydrolase. <b>2011</b> , 133, 1553-62	23
929	Visual characterization and diversity quantification of chemical libraries: 1. creation of delimited reference chemical subspaces. <b>2011</b> , 51, 1762-74	28
928	Route to three-dimensional fragments using diversity-oriented synthesis. <b>2011</b> , 108, 6799-804	207
927	The use of GPCR structures in drug design. <b>2011</b> , 62, 1-36	34
926	Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. <b>2011</b> , 493, 115-36	91
925	Fragment screening using X-ray crystallography. <b>2012</b> , 317, 33-59	60
924	Scenarios and Case Studies: Examples for Ligand-Based Virtual Screening. <b>2011</b> , 359-379	1
923	Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis. <b>2011</b> , 133, 5363-71	63
922	A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. <b>2011</b> , 54, 7784-96	72
921	How to avoid rediscovering the known. <b>2011</b> , 493, 159-68	1
920	Using computational techniques in fragment-based drug discovery. <b>2011</b> , 493, 137-55	10
919	Practical aspects of NMR-based fragment screening. <b>2011</b> , 493, 219-39	50
918	Designing a diverse high-quality library for crystallography-based FBDD screening. <b>2011</b> , 493, 3-20	16
917	Key factors for successful generation of protein-fragment structures requirement on protein, crystals, and technology. <b>2011</b> , 493, 61-89	15
916	Predicting the success of fragment screening by X-ray crystallography. <b>2011</b> , 493, 91-114	9

915	Fragment screening of infectious disease targets in a structural genomics environment. <b>2011</b> , 493, 533-56	5
914	Fragment screening purely with protein crystallography. <b>2011</b> , 493, 321-56	19
913	Chemoinformatics and Computational Chemical Biology. <b>2011</b> ,	6
912	Fragment-based drug design. <b>2011</b> , 685, 241-52	13
911	Design of screening collections for successful fragment-based lead discovery. <b>2011</b> , 685, 219-40	2
910	Introduction to fragment-based drug discovery. <b>2012</b> , 317, 1-32	142
909	Computational medicinal chemistry in fragment-based drug discovery: what, how and when. <b>2011</b> , 3, 95-134	16
908	Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors. <b>2012</b> , 317, 83-114	44
907	Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. <b>2011</b> , 24, 1420-56	371
906	Fragment-based approaches and computer-aided drug discovery. <b>2012</b> , 317, 201-22	22
905	Emerging role of surface plasmon resonance in fragment-based drug discovery. <b>2011</b> , 3, 1809-20	44
904	Definition of drug-likeness for compound affinity. <b>2011</b> , 51, 1012-6	7
903	Spirocyclic systems derived from pyroglutamic acid. <b>2011</b> , 9, 7042-56	11
902	. <b>2011</b> ,	6
901	. <b>2011</b> ,	13
900	The Pyramid Approach to Fragment-Based Biophysical Screening. <b>2011</b> , 241-253	2
899	SPR Screening of Chemical Microarrays for Fragment-Based Discovery. <b>2011</b> , 41-55	1
898	Novel chiral skeletons for drug discovery: antibacterial tetramic acids. <b>2011</b> , 78, 229-35	23

897	Targeting metalloproteins by fragment-based lead discovery. <b>2011</b> , 78, 211-23	13
896	Identification of agents that induce apoptosis of multicellular tumour spheroids: enrichment for mitotic inhibitors with hydrophobic properties. <b>2011</b> , 78, 547-57	33
895	Probing the links between in vitro potency, ADMET and physicochemical parameters. <b>2011</b> , 10, 197-208	333
894	Synthesis and solid state study of pyridine- and pyrimidine-based fragment libraries. <b>2011</b> , 52, 5905-5909	8
893	Acetylcholine binding protein (AChBP) as template for hierarchical in silico screening procedures to identify structurally novel ligands for the nicotinic receptors. <b>2011</b> , 19, 6107-19	25
892	Fragment-Based Drug Discovery for Diseases of the Central Nervous System. <b>2011</b> , 179-192	
891	Fragment-Based High-Throughput Docking and Library Tailoring. <b>2011</b> , 131-147	
890	Design and Application of Fragment Libraries for Protein Crystallography. <b>2011</b> , 45-56	
889	Selectivity of kinase inhibitor fragments. <b>2011</b> , 54, 5131-43	62
888	Docking performance of fragments and druglike compounds. <b>2011</b> , 54, 5422-31	94
887	Preparing and Filtering Compound Databases for Virtual and Experimental Screening. <b>2011</b> , 35-59	6
886	Probing the druggability of protein-protein interactions: targeting the Notch1 receptor ankyrin domain using a fragment-based approach. <b>2011</b> , 39, 1327-33	15
885	Cheminformatics: a history. <b>2011</b> , 1, 46-56	37
884	Structure-guided fragment-based in silico drug design of dengue protease inhibitors. <b>2011</b> , 25, 263-74	46
883	Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics. <b>2011</b> , 25, 621-36	50
882	Visualisation and subsets of the chemical universe database GDB-13 for virtual screening. <b>2011</b> , 25, 637-47	40
881	Visualisation of the chemical space of fragments, lead-like and drug-like molecules in PubChem. <b>2011</b> , 25, 649-62	26
880	A comparative study of fragment screening methods on the p38 $\beta$ kinase: new methods, new insights. <b>2011</b> , 25, 677-87	30

879	Design and evaluation of 3-aminopyrazolopyridinone kinase inhibitors inspired by the natural product indirubin. <b>2011</b> , 19, 3569-78	13
878	In-crystal affinity ranking of fragment hit compounds reveals a relationship with their inhibitory activities. <b>2011</b> , 44, 798-804	15
877	Ligand Efficiency Indices (LEIs): More than a Simple Efficiency Yardstick. <b>2011</b> , 30, 122-32	21
876	Molecular complexity and fragment-based drug discovery: ten years on. <b>2011</b> , 15, 489-96	129
875	High concentration electrophysiology-based fragment screen: discovery of novel acid-sensing ion channel 3 (ASIC3) inhibitors. <b>2011</b> , 21, 2646-9	13
874	The benefits of constructing leads from fragment hits. <b>2011</b> , 3, 1111-5	25
873	New strategies in the discovery of novel non-camptothecin topoisomerase I inhibitors. <b>2011</b> , 18, 4389-409	33
872	Fragment-based drug design: computational & experimental state of the art. <b>2011</b> , 14, 500-20	27
871	Fragment screening and HIV therapeutics. <b>2012</b> , 317, 181-200	17
870	Development and validation of a yeast high-throughput screen for inhibitors of A $\beta$ oligomerization. <b>2011</b> , 4, 822-31	38
869	Experimental validation of a fragment library for lead discovery using SPR biosensor technology. <b>2011</b> , 16, 15-25	26
868	FragmentStore--a comprehensive database of fragments linking metabolites, toxic molecules and drugs. <b>2011</b> , 39, D1049-54	17
867	Fragment-based screening by protein crystallography: successes and pitfalls. <b>2012</b> , 13, 12857-79	40
866	Integrated ligand based pharmacophore model derived from diverse FAAH covalent ligand classes. <b>2012</b> , 8, 330-4	
865	Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening. <b>2012</b> , 12, 1500-13	40
864	QSPR in oral bioavailability: specificity or integrality?. <b>2012</b> , 12, 534-50	12
863	Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. <b>2012</b> , 45, 383-426	74
862	Fragment based drug design: from experimental to computational approaches. <b>2012</b> , 19, 5128-47	94



861	Using fragment-based technologies to target protein-protein interactions. <b>2012</b> , 18, 4685-96	25
860	Targeting cancer using fragment based drug discovery. <b>2012</b> , 12, 40-8	6
859	From laptop to benchtop to bedside: structure-based drug design on protein targets. <b>2012</b> , 18, 1217-39	53
858	Unrestricted Vision. <b>2012</b> , 01,	2
857	A Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine Kinases. <b>2012</b> , 3, 342-6	18
856	Combinatorial synthesis of chemical building blocks 1. Azomethines. <b>2012</b> , 16, 625-37	4
855	Virtual fragment screening: discovery of histamine H3 receptor ligands using ligand-based and protein-based molecular fingerprints. <b>2012</b> , 52, 3308-24	55
854	Dissecting fragment-based lead discovery at the von Hippel-Lindau protein: hypoxia inducible factor 1 $\beta$ protein-protein interface. <b>2012</b> , 19, 1300-12	129
853	Privileged structures - dream or reality: preferential organization of azanaphthalene scaffold. <b>2012</b> , 19, 1921-45	46
852	Strategies for the generation, validation and application of in silico ADMET models in lead generation and optimization. <b>2012</b> , 8, 1435-46	16
851	An integrated fragment based screening approach for the discovery of small molecule modulators of the VWF-GPIb $\beta$ interaction. <b>2012</b> , 48, 11349-51	8
850	Recent trends and applications in 3D virtual screening. <b>2012</b> , 15, 749-69	12
849	Fighting high molecular weight in bioactive molecules with sub-pharmacophore-based virtual screening. <b>2012</b> , 52, 380-90	
848	Visual characterization and diversity quantification of chemical libraries: 2. Analysis and selection of size-independent, subspace-specific diversity indices. <b>2012</b> , 52, 327-42	11
847	Fragment screening using capillary electrophoresis (CEfrag) for hit identification of heat shock protein 90 ATPase inhibitors. <b>2012</b> , 17, 868-76	41
846	Focused enumeration and assessing the structural diversity of scaffold libraries: conformationally restricted bicyclic secondary diamines. <b>2012</b> , 16, 477-87	16
845	e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design. <b>2012</b> , 28, 1540-1	77
844	Spiro-fused pyrrolidine, piperidine, and oxindole scaffolds from lactams. <b>2012</b> , 14, 4846-9	31

843	Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes. <b>2012</b> , 55, 6455-66	47
842	In silico design of small molecules. <b>2012</b> , 800, 25-31	5
841	Going further than Lipinski's rule in drug design. <b>2012</b> , 7, 99-107	91
840	Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity. <b>2012</b> , 7, 2064-73	69
839	Plane of best fit: a novel method to characterize the three-dimensionality of molecules. <b>2012</b> , 52, 2516-25	71
838	Fragment screening of cyclin G-associated kinase by weak affinity chromatography. <b>2012</b> , 404, 2417-25	22
837	Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor. <b>2012</b> , 55, 8807-26	58
836	Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90. <b>2012</b> , 22, 4396-403	13
835	Reagent-based DOS: developing a diastereoselective methodology to access spirocyclic- and fused heterocyclic ring systems. <b>2012</b> , 7, 2351-60	14
834	Mining collections of compounds with Screening Assistant 2. <b>2012</b> , 4, 20	24
833	INPHARMA-based identification of ligand binding site in fragment-based drug design. <b>2012</b> , 3, 605	14
832	Discovery of structurally-diverse inhibitor scaffolds by high-throughput screening of a fragment library with dimethylarginine dimethylaminohydrolase. <b>2012</b> , 20, 5550-8	12
831	Halogen-enriched fragment libraries as leads for drug rescue of mutant p53. <b>2012</b> , 134, 6810-8	159
830	Whole-genome sequence of <i>Schistosoma haematobium</i> . <b>2012</b> , 44, 221-5	325
829	Automated protein-ligand interaction screening by mass spectrometry. <b>2012</b> , 55, 837-51	57
828	Medicinal Chemistry and Ligand Profiling for Evaluation of Promising Marine Bioactive Molecules. <b>2012</b> , 173-206	1
827	Fragment library design considerations. <b>2012</b> , 2, 868-885	12
826	The enumeration of chemical space. <b>2012</b> , 2, 717-733	67

825	Implications of promiscuous Pim-1 kinase fragment inhibitor hydrophobic interactions for fragment-based drug design. <b>2012</b> , 55, 2641-8	25
824	Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. <b>2012</b> , 55, 576-86	162
823	Aromatic cations from oxidative carbon-hydrogen bond cleavage in bimolecular carbon-carbon bond forming reactions. <b>2012</b> , 77, 6574-82	55
822	Chapter 4:Bioavailability Prediction at Early Drug Discovery Stages: In Vitro Assays and Simple Physico-Chemical Rules. <b>2012</b> , 104-127	4
821	Chapter 12:Expanding the Target Space: Druggability Assessments. <b>2012</b> , 302-318	
820	Chapter 9:In Silico Lead Generation Approaches in Multi-Target Drug Discovery. <b>2012</b> , 130-140	2
819	CHAPTER 3:Leukotriene A4 Hydrolase: Biology, Inhibitors and Clinical Applications. <b>2012</b> , 58-103	2
818	Analysis of structure-based virtual screening studies and characterization of identified active compounds. <b>2012</b> , 4, 603-13	35
817	Exploring chemical space for drug discovery using the chemical universe database. <b>2012</b> , 3, 649-57	165
816	Leitstruktur-orientierte Synthese: eine Alternative für die Synthesechemie. <b>2012</b> , 124, 1140-1149	67
815	Application of Barluenga Boronic Coupling (BBC) to the parallel synthesis of drug-like and drug fragment-like molecules. <b>2012</b> , 7, 233-6	30
814	Fragment-based approaches in drug discovery and chemical biology. <b>2012</b> , 51, 4990-5003	315
813	Quantifying the chemical beauty of drugs. <b>2012</b> , 4, 90-8	664
812	Computational fragment-based screening using RosettaLigand: the SAMPL3 challenge. <b>2012</b> , 26, 603-16	13
811	Combinatorially-generated library of 6-fluoroquinolone analogs as potential novel antitubercular agents: a chemometric and molecular modeling assessment. <b>2012</b> , 18, 1735-53	24
810	Hit clustering can improve virtual fragment screening: CDK2 and PARP1 case studies. <b>2012</b> , 18, 2553-66	6
809	Structural biology and drug discovery of difficult targets: the limits of ligandability. <b>2012</b> , 19, 42-50	159
808	The role of fragment-based and computational methods in polypharmacology. <i>Drug Discovery Today</i> , <b>2012</b> , 17, 23-34	8.8 95

807	Physicochemical profile of macrolides and their comparison with small molecules. <b>2012</b> , 47, 462-72		26
806	Novel diversely substituted 1-heteroaryl-2-imidazolines for fragment-based drug discovery. <b>2012</b> , 53, 2876-2880		23
805	Lead-oriented synthesis: a new opportunity for synthetic chemistry. <b>2012</b> , 51, 1114-22		295
804	The future of molecular dynamics simulations in drug discovery. <b>2012</b> , 26, 15-26		179
803	Fragment informatics and computational fragment-based drug design: an overview and update. <b>2013</b> , 33, 554-98		36
802	The 'rule of three' for fragment-based drug discovery: where are we now?. <b>2013</b> , 12, 644-5		168
801	Navigating in Chemicobiological Space. <b>2013</b> , 91-105		
800	Protein crystallography and fragment-based drug design. <b>2013</b> , 5, 1121-40		25
799	Fragment-based hit identification: thinking in 3D. <i>Drug Discovery Today</i> , <b>2013</b> , 18, 1221-7	8.8	100
798	Bimolecular Coupling Reactions through Oxidatively Generated Aromatic Cations: Scope and Stereocontrol. <b>2013</b> , 69, 7618-7626		38
797	Correlations between the selected parameters of the chemical structure of drugs and between-subject variability in area under the curve. <b>2013</b> , 22, 1812-1824		
796	Synthesis of trans-2-(trifluoromethyl)cyclopropanes via Suzuki reactions with an N-methyliminodiacetic acid boronate. <b>2013</b> , 15, 4284-7		45
795	Comparative amino acid decomposition analysis of potent type I p38 $\beta$ inhibitors. <b>2013</b> , 21, 41		4
794	Insights into the immuno-molecular biology of <i>Angiostrongylus vasorum</i> through transcriptomics--prospects for new interventions. <b>2013</b> , 31, 1486-500		16
793	Construction of the CSIRO Fragment Library. <b>2013</b> , 66, 1473		8
792	Design and Evaluation of the Performance of an NMR Screening Fragment Library. <b>2013</b> , 66, 1465		30
791	Multitarget fragment-based design of novel inhibitors for AChE and SSAO/VAP-1 enzymes. <b>2013</b> , 27, 297-305		1
790	The small molecule drug discovery process [From target selection to candidate selection. <b>2013</b> , 81-126		6

789	Chemical predictive modelling to improve compound quality. <b>2013</b> , 12, 948-62	157
788	De Novo Design by Fragment Growing and Docking. <b>2013</b> , 125-142	2
787	Hit and Lead Identification from Fragments. <b>2013</b> , 143-200	1
786	NMR study to identify a ligand-binding pocket in Ras. <b>2013</b> , 33 Pt A, 15-39	7
785	Exploring the chemical space of multitarget ligands using aligned self-organizing maps. <b>2013</b> , 4, 1169-72	30
784	Probing structural adaptivity at PPI interfaces with small molecules. <b>2013</b> , 10, e501-8	19
783	Computer-aided design, synthesis and validation of 2-phenylquinazolinone fragments as CDK9 inhibitors with anti-HIV-1 Tat-mediated transcription activity. <b>2013</b> , 8, 1941-53	23
782	Discovery of a potent inhibitor of replication protein a protein-protein interactions using a fragment-linking approach. <b>2013</b> , 56, 9242-50	48
781	Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors. <b>2013</b> , 53, 2715-29	22
780	SMIfp (SMILES fingerprint) chemical space for virtual screening and visualization of large databases of organic molecules. <b>2013</b> , 53, 1979-89	45
779	Development of fragment-based n-FABS NMR screening applied to the membrane enzyme FAAH. <b>2013</b> , 14, 1611-9	16
778	Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists. <b>2013</b> , 21, 2045-55	26
777	Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification?. <b>2013</b> , 18, 147-59	57
776	Visualization and virtual screening of the chemical universe database GDB-17. <b>2013</b> , 53, 56-65	78
775	Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. <b>2013</b> , 56, 15-30	206
774	Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors. <b>2013</b> , 56, 1023-40	71
773	S4MPLE--sampler for multiple protein-ligand entities: simultaneous docking of several entities. <b>2013</b> , 53, 88-102	20
772	Broad coverage of commercially available lead-like screening space with fewer than 350,000 compounds. <b>2013</b> , 53, 39-55	54

771	Natural-product-derived fragments for fragment-based ligand discovery. <b>2013</b> , 5, 21-8		207
770	Identification of fragments targeting an alternative pocket on HIV-1 gp41 by NMR screening and similarity searching. <b>2013</b> , 23, 5114-8		17
769	Subpocket analysis method for fragment-based drug discovery. <b>2013</b> , 53, 131-41		14
768	Copper-catalyzed N-arylation of 2-imidazolines with aryl iodides. <b>2013</b> , 78, 3470-5		25
767	Synthesis of privileged scaffolds by using diversity-oriented synthesis. <b>2013</b> , 8, 1168-76		9
766	Development of a natural products database from the biodiversity of Brazil. <b>2013</b> , 76, 439-44		101
765	Small molecule regulation of protein conformation by binding in the Flap of HIV protease. <b>2013</b> , 8, 1223-31		27
764	Advances in the design of a multipurpose fragment screening library. <b>2013</b> , 8, 597-606		15
763	In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE. <b>2013</b> , 53, 836-51		28
762	Small and colorful stones make beautiful mosaics: fragment-based chemogenomics. <i>Drug Discovery Today</i> , <b>2013</b> , 18, 323-30	8.8	26
761	Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file. <b>2013</b> , 17, 319-35		7
760	De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments. <b>2013</b> , 8, 1044-52		39
759	Tetrahydropyrido[d]pyridazinones—promising scaffolds for drug discovery. <b>2013</b> , 69, 6799-6803		5
758	A reagent based DOS strategy via Evans chiral auxiliary: highly stereoselective Michael reaction towards optically active quinolizidinones, piperidinones and pyrrolidinones. <b>2013</b> , 3, 2404		8
757	Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach. <b>2013</b> , 59, 141-9		23
756	Fragment-based drug discovery using NMR spectroscopy. <b>2013</b> , 56, 65-75		147
755	Nanomolar E-selectin antagonists with prolonged half-lives by a fragment-based approach. <b>2013</b> , 135, 9820-8		47
754	The Basics of Diversity-Oriented Synthesis. <b>2013</b> , 1-26		7

753	Chemoinformatic Characterization of the Chemical Space and Molecular Diversity of Compound Libraries. <b>2013</b> , 325-352	6
752	Diversity-Oriented Synthesis of Amino Acid Derived Scaffolds and Peptidomimetics: A Perspective. <b>2013</b> , 177-200	
751	Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain. <b>2013</b> , 56, 3833-51	99
750	Discovery of a New Class of Potent MMP Inhibitors by Structure-Based Optimization of the Arylsulfonamide Scaffold. <b>2013</b> , 4, 565-9	15
749	Ask the experts: past, present and future of the rule of five. <b>2013</b> , 5, 745-52	21
748	A three-stage biophysical screening cascade for fragment-based drug discovery. <b>2013</b> , 8, 2309-24	103
747	Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain. <b>2013</b> , 56, 10183-7	85
746	Vaccine safety and quality assessments. <b>2013</b> , 111-122	
745	Vaccine adjuvant informatics. <b>2013</b> , 123-130	1
744	Ligand binding and aggregation of pathogenic SOD1. <b>2013</b> , 4, 1758	72
743	X-ray Crystallography and Computational Docking for the Detection and Development of Protein-Ligand Interactions. <b>2013</b> , 20, 569-575	
742	Impact of physicochemical profiling for rational approach on drug discovery. <b>2013</b> , 61, 1228-38	27
741	Structure-Based Drug Design. <b>2013</b> , 01,	2
740	Virtual screening strategies in drug discovery: a critical review. <b>2013</b> , 20, 2839-60	363
739	Structure-based virtual screening for drug discovery: principles, applications and recent advances. <b>2014</b> , 14, 1923-38	481
738	Open Innovation Drug Discovery (OIDD): a potential path to novel therapeutic chemical space. <b>2014</b> , 14, 294-303	30
737	Fragment-based drug discovery and protein-protein interactions. <b>2014</b> , 13	12
736	. <b>2014</b> ,	20

735	. <b>2014</b> ,	36
734	Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands. <b>2014</b> , 6, 179-204	27
733	Structural Biology and Anticancer Drug Design. <b>2014</b> , 121-141	1
732	The ChEMBL bioactivity database: an update. <b>2014</b> , 42, D1083-90	1052
731	Cofactor-independent phosphoglycerate mutase from nematodes has limited druggability, as revealed by two high-throughput screens. <b>2014</b> , 8, e2628	17
730	Modified N,O-Nucleosides: Design, Synthesis, and Anti-tumour Activity. <b>2014</b> , 67, 670	8
729	Knowledge-based fragment binding prediction. <b>2014</b> , 10, e1003589	18
728	The ChEMBL database: a taster for medicinal chemists. <b>2014</b> , 6, 361-4	32
727	A chemo-centric view of human health and disease. <b>2014</b> , 5, 5676	17
726	Foodinformatics. <b>2014</b> ,	9
725	Fragment-based approaches to the discovery of kinase inhibitors. <b>2014</b> , 548, 69-92	9
724	Using chiral molecules as an approach to address low-druggability recognition sites. <b>2014</b> , 35, 2114-21	4
723	Computational approaches for drug discovery. <b>2014</b> , 75, 412-8	52
722	Repositioning the substrate activity screening (SAS) approach as a fragment-based method for identification of weak binders. <b>2014</b> , 15, 2238-47	7
721	BioPhytMol: a drug discovery community resource on anti-mycobacterial phytomolecules and plant extracts. <b>2014</b> , 6, 46	26
720	A multi-fingerprint browser for the ZINC database. <b>2014</b> , 42, W234-9	30
719	Discovery of ATP-Competitive Inhibitors of tRNA <sup>Ala</sup> Lysidine Synthetase (Tils) by High-Throughput Screening. <b>2014</b> , 19, 1137-46	1
718	Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens. <b>2014</b> , 83, 38-51	24



717	Searching for protein binding sites from Molecular Dynamics simulations and paramagnetic fragment-based NMR studies. <b>2014</b> , 1844, 561-6	17
716	NMR-based approaches for the identification and optimization of inhibitors of protein-protein interactions. <b>2014</b> , 114, 4749-63	78
715	Hot spot-based design of small-molecule inhibitors for protein-protein interactions. <b>2014</b> , 24, 2546-54	106
714	De novo design of multitarget ligands with an iterative fragment-growing strategy. <b>2014</b> , 54, 1235-41	40
713	Fragment-based lead discovery and design. <b>2014</b> , 54, 693-704	96
712	P2X3 and P2X2/3 receptor antagonists. <b>2014</b> , 3, 53-64	8
711	Begin with the End in Mind. <b>2014</b> , 231-245	
710	A fragment-based method to discover irreversible covalent inhibitors of cysteine proteases. <b>2014</b> , 57, 4969-74	127
709	Rings in drugs. <b>2014</b> , 57, 5845-59	1190
708	Increasing the coverage of medicinal chemistry-relevant space in commercial fragments screening. <b>2014</b> , 54, 79-85	18
707	Positive allosteric modulators of 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors belonging to 4-cyclopropyl-3,4-dihydro-2H-1,2,4-pyridothiadiazine dioxides and diversely chloro-substituted 4-cyclopropyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides. <b>2014</b> , 57, 9539-53	19
706	Lead Discovery and Lead Modification. <b>2014</b> , 19-122	5
705	2-(Aryl-sulfonyl)oxetanes as designer 3-dimensional fragments for fragment screening: synthesis and strategies for functionalisation. <b>2014</b> , 50, 5203-5	45
704	Two- and three-dimensional rings in drugs. <b>2014</b> , 83, 450-61	142
703	Pyrrolidine and piperidine based chiral spiro and fused scaffolds via build/couple/pair approach. <b>2014</b> , 4, 10619	4
702	Targeting a c-MYC G-quadruplex DNA with a fragment library. <b>2014</b> , 50, 1704-7	41
701	n-Alkylboronic acid inhibitors reveal determinants of ligand specificity in the quorum-quenching and siderophore biosynthetic enzyme PvdQ. <b>2014</b> , 53, 6679-86	13
700	sc-PDB-Frag: a database of protein-ligand interaction patterns for Bioisosteric replacements. <b>2014</b> , 54, 1908-18	15

699	Yeast synthetic biology platform generates novel chemical structures as scaffolds for drug discovery. <b>2014</b> , 3, 314-23	46
698	Improving the use of ranking in virtual screening against HIV-1 integrase with triangular numbers and including ligand profiling with antitargets. <b>2014</b> , 54, 3172-85	10
697	Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes. <b>2014</b> , 57, 3522-31	74
696	Regio- and stereospecific synthesis of C-3 functionalized proline derivatives by palladium catalyzed directed C(sp <sup>3</sup> )-H arylation. <b>2014</b> , 16, 4956-9	114
695	Para-(benzoyl)-phenylalanine as a potential inhibitor against LpxC of <i>Leptospira</i> spp.: homology modeling, docking, and molecular dynamics study. <b>2014</b> , 32, 171-85	37
694	Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein-Protein Interactions?. <b>2014</b> , 5, 23-28	44
693	Computer-aided discovery of <i>Trypanosoma brucei</i> RNA-editing terminal uridylyl transferase 2 inhibitors. <b>2014</b> , 84, 131-9	10
692	Identification of novel leads applying in silico studies for <i>Mycobacterium</i> multidrug resistant (MMR) protein. <b>2014</b> , 32, 1889-906	15
691	Synthesis of novel bridged dinitrogen heterocycles and their evaluation as potential fragments for the design of biologically active compounds. <b>2014</b> , 70, 7854-7864	16
690	Expanding the fragrance chemical space for virtual screening. <b>2014</b> , 6, 27	25
689	Atom pair 2D-fingerprints perceive 3D-molecular shape and pharmacophores for very fast virtual screening of ZINC and GDB-17. <b>2014</b> , 54, 1892-907	45
688	Synthesis, screening and docking of small heterocycles as glycogen phosphorylase inhibitors. <b>2014</b> , 84, 584-94	9
687	Biased and unbiased strategies to identify biologically active small molecules. <b>2014</b> , 22, 4474-89	12
686	Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery. <b>2014</b> , 6, 617-39	30
685	Ligand-Based Virtual Screening using Random Walk Kernel and Empirical Filters. <b>2015</b> , 57, 418-427	3
684	Elements for the Development of Strategies for Compound Library Enhancement. <b>2015</b> , 11-36	
683	Advances in the Understanding of Drug Properties in Medicinal Chemistry. <b>2015</b> , 305-322	1
682	Computational Techniques to Support Hit Triage. <b>2015</b> , 189-220	3

681	Virtual Screening. <b>2015</b> , 251-280	2
680	Selective Targeting of the TPX2 Site of Importin- $\beta$ Using Fragment-Based Ligand Design. <b>2015</b> , 10, 1232-9	10
679	Thermodynamics-Guided Optimizations in Medicinal Chemistry. <b>2015</b> , 63-80	
678	-MM-GB/SA Rescoring of Docking Poses: Tricks of the Trade. <b>2015</b> , 310-329	
677	Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model. <b>2015</b> , 5, 16300	25
676	Protein X-Ray Crystallography in Structure-Based Drug Design. <b>2015</b> , 183-198	
675	In silico ADME/T modelling for rational drug design. <b>2015</b> , 48, 488-515	137
674	Discovery of Small Molecules that Inhibit the Disordered Protein, p27(Kip1). <b>2015</b> , 5, 15686	54
673	Revealing the Macromolecular Targets of Fragment-Like Natural Products. <b>2015</b> , 127, 10662-10666	19
672	Identification of structure-activity relationships from screening a structurally compact DNA-encoded chemical library. <b>2015</b> , 54, 3927-31	73
671	A Mini-review on Chemoinformatics Approaches for Drug Discovery. <b>2015</b> , 16, 15-29	6
670	Revealing the Macromolecular Targets of Fragment-Like Natural Products. <b>2015</b> , 54, 10516-20	47
669	One Question, Multiple Answers: Biochemical and Biophysical Screening Methods Retrieve Deviating Fragment Hit Lists. <b>2015</b> , 10, 1511-21	43
668	[5-(Benzyloxy)-1H-indol-1-yl]acetic acid, an aldose reductase inhibitor and PPAR $\alpha$ ligand. <b>2015</b> , 62, 523-8	5
667	Charting a Path to Success in Virtual Screening. <b>2015</b> , 20, 18732-58	52
666	Pharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts and Applications Exemplified on Hydroxysteroid Dehydrogenases. <b>2015</b> , 20, 22799-832	80
665	A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets. <b>2015</b> , 6, 197	19
664	Fragment-based drug discovery and molecular docking in drug design. <b>2015</b> , 16, 11-25	41

663	Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidiothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells. <b>2015</b> , 20, 9879-89	4
662	Capturing nature's diversity. <b>2015</b> , 10, e0120942	31
661	[Fragment-based screening: a promising avenue for drug design]. <b>2015</b> , 31, 197-202	0
660	Understanding the foundations of the structural similarities between marketed drugs and endogenous human metabolites. <b>2015</b> , 6, 105	26
659	Identification of amino acids involved in histamine potentiation of GABA A receptors. <b>2015</b> , 6, 106	5
658	. <b>2015</b> ,	5
657	Protein-Protein Interactions: Structures and Druggability. <b>2015</b> , 141-163	4
656	Fragment growing exploiting dynamic combinatorial chemistry of inhibitors of the aspartic protease endothiapepsin. <b>2015</b> , 6, 1267-1271	14
655	The impact of physicochemical and molecular properties in drug design: navigation in the "drug-like" chemical space. <b>2015</b> , 822, 187-94	14
654	Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening. <b>2015</b> , 112, 6979-84	13
653	Tankyrase 1 Inhibitors with Drug-like Properties Identified by Screening a DNA-Encoded Chemical Library. <b>2015</b> , 58, 5143-9	54
652	FAF-Drugs3: a web server for compound property calculation and chemical library design. <b>2015</b> , 43, W200-7	192
651	Computational Fragment-Based Drug Design. <b>2015</b> , 189-215	
650	Identification of Structure-Activity Relationships from Screening a Structurally Compact DNA-Encoded Chemical Library. <b>2015</b> , 127, 3999-4003	12
649	A 'rule of 0.5' for the metabolite-likeness of approved pharmaceutical drugs. <b>2015</b> , 11, 323-339	60
648	The chemical space project. <b>2015</b> , 48, 722-30	289
647	Chemical Biology. <b>2015</b> ,	13
646	Efficient and facile synthesis of acrylamide libraries for protein-guided tethering. <b>2015</b> , 17, 458-60	13

645	A desirability function-based scoring scheme for selecting fragment-like class A aminergic GPCR ligands. <b>2015</b> , 29, 59-66		6
644	Multifaceted Roles of Crystallography in Modern Drug Discovery. <b>2015</b> ,		1
643	Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation. <b>2015</b> , 58, 2265-74		84
642	Fragment-Based Methods in Drug Discovery. <b>2015</b> ,		3
641	Fragment-based design of kinase inhibitors: a practical guide. <b>2015</b> , 1289, 157-83		3
640	Role of computer-aided drug design in modern drug discovery. <b>2015</b> , 38, 1686-701		272
639	State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors. <b>2015</b> , 44, 8238-59		104
638	Open Drug Discovery Toolkit (ODDT): a new open-source player in the drug discovery field. <b>2015</b> , 7, 26		69
637	Development of HIV-1 integrase inhibitors: recent molecular modeling perspectives. <i>Drug Discovery Today</i> , <b>2015</b> , 20, 1337-48	8.8	10
636	Fragment-Based Drug Discovery. <b>2015</b> , 161-180		7
635	Protein Crystallography and Drug Discovery. <b>2015</b> , 511-537		3
634	Facile access to a heterocyclic, sp <sup>3</sup> -rich chemical scaffold via a tandem condensation/intramolecular nitrene-alkene [3+2] cycloaddition strategy. <b>2015</b> , 51, 12867-70		20
633	Progress in visual representations of chemical space. <b>2015</b> , 10, 959-73		50
632	Fragments in bromodomain drug discovery. <b>2015</b> , 6, 1587-1604		15
631	The purchasable chemical space: a detailed picture. <b>2015</b> , 55, 915-24		32
630	Structure-based virtual screening for fragment-like ligands of the G protein-coupled histamine H4 receptor. <b>2015</b> , 6, 1003-1017		27
629	Detailed atomistic molecular modeling of a potent type 1b38 inhibitor. <b>2015</b> , 26, 1125-1137		3
628	Identification of binding sites and favorable ligand binding moieties by virtual screening and self-organizing map analysis. <b>2015</b> , 16, 93		11

627	Stereoselective virtual screening of the ZINC database using atom pair 3D-fingerprints. <b>2015</b> , 7, 3	42
626	Molecular dynamics to enhance structure-based virtual screening on cathepsin B. <b>2015</b> , 29, 707-12	13
625	Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90. <b>2015</b> , 76, 83-94	12
624	Ligand deconstruction: Why some fragment binding positions are conserved and others are not. <b>2015</b> , 112, E2585-94	47
623	Studies on the synthesis, stability and conformation of 2-sulfonyl-oxetane fragments. <b>2015</b> , 13, 5265-72	20
622	Sources for Leads: Natural Products and Libraries. <b>2016</b> , 232, 91-123	7
621	Ligand-Orientation Based Fragment Selection in STD NMR Screening. <b>2015</b> , 58, 8739-42	38
620	Post-HTS case report and structural alert: Promiscuous 4-aryl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR. <b>2015</b> , 25, 4740-4752	15
619	Multicomponent assembly of 4-aza-podophyllotoxins: A fast entry to highly selective and potent anti-leukemic agents. <b>2015</b> , 106, 167-79	17
618	Probing metallo- $\beta$ -lactamases with molecular fragments identified by consensus docking. <b>2015</b> , 25, 5243-6	16
617	Accurate Binding Free Energy Predictions in Fragment Optimization. <b>2015</b> , 55, 2411-20	83
616	Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors. <b>2015</b> , 58, 6928-37	19
615	Steering the azido-tetrazole equilibrium of 4-azidopyrimidines via substituent variation - implications for drug design and azide-alkyne cycloadditions. <b>2015</b> , 13, 10620-30	13
614	One cannot rule them all: Are bacterial toxins-antitoxins druggable?. <b>2015</b> , 39, 522-40	57
613	Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities. <b>2015</b> , 10, 1271-81	6
612	Emerging Target Families: Intractable Targets. <b>2016</b> , 232, 43-58	8
611	A fluorescent approach for identifying P2X1 ligands. <b>2015</b> , 98, 13-21	8
610	Biomedical potential of natural products derived through metagenomic approaches. <b>2015</b> , 5, 101200-101213	0

609	A Prospective Method To Guide Small Molecule Drug Design. <b>2015</b> , 92, 836-842		7
608	Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling. <b>2015</b> , 71, 113-34		51
607	Evolutions in fragment-based drug design: the deconstruction-reconstruction approach. <i>Drug Discovery Today</i> , <b>2015</b> , 20, 105-13	8.8	80
606	GeNeDis 2014. <b>2015</b> ,		0
605	Novel approaches for targeting the adenosine A2A receptor. <b>2015</b> , 10, 63-80		9
604	Designing novel building blocks is an overlooked strategy to improve compound quality. <i>Drug Discovery Today</i> , <b>2015</b> , 20, 11-7	8.8	141
603	Handbook of Drug Screening. <b>2016</b> ,		2
602	Going Small: Using Biophysical Screening to Implement Fragment Based Drug Discovery. <b>2016</b> ,		1
601	The Role of Biotin in Bacterial Physiology and Virulence: a Novel Antibiotic Target for <i>Mycobacterium tuberculosis</i> . <b>2016</b> , 797-822		3
600	Quantitative Structure-Activity Relationships. <b>2016</b> , 163-192		4
599	Identification of a Fragment-Based Scaffold that Inhibits the Glycosyltransferase WaaG from <i>Escherichia coli</i> . <b>2016</b> , 5,		2
598	Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs. <b>2016</b> , 21, 75		39
597	Fragment-Based Whole Cell Screen Delivers Hits against <i>M. tuberculosis</i> and Non-tuberculous <i>Mycobacteria</i> . <b>2016</b> , 7, 1392		13
596	Process of Fragment-Based Lead Discovery-A Perspective from NMR. <b>2016</b> , 21,		20
595	Computational methods in drug discovery. <b>2016</b> , 12, 2694-2718		271
594	. <b>2016</b> ,		18
593	The use of conformationally thermostabilised GPCRs in drug discovery: application to fragment, structure and biophysical techniques. <b>2016</b> , 30, 8-13		12
592	Fragment-Based Lead Generation. <b>2016</b> , 133-158		

591	Lead Quality. <b>2016</b> , 451-486	3
590	The Microphysiology Systems Database for Analyzing and Modeling Compound Interactions with Human and Animal Organ Models. <b>2016</b> , 2, 103-117	18
589	Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes Insipidus. <b>2016</b> , 21, 824-31	19
588	The Role of Biotin in Bacterial Physiology and Virulence: a Novel Antibiotic Target for <i>Mycobacterium tuberculosis</i> . <b>2016</b> , 4,	33
587	Divergent Synthesis and Real-Time Biological Annotation of Optically Active Tetrahydrocyclopenta[c]pyranone Derivatives. <b>2016</b> , 18, 6280-6283	9
586	Small Molecules Antagonise the MIA-Fibronectin Interaction in Malignant Melanoma. <b>2016</b> , 6, 25119	6
585	Structures of endothiapsin-fragment complexes from crystallographic fragment screening using a novel, diverse and affordable 96-compound fragment library. <b>2016</b> , 72, 346-55	22
584	Fragment-Based Screening for Enzyme Inhibitors Using Calorimetry. <b>2016</b> , 567, 47-69	6
583	Yeast as a tool to select inhibitors of the cullin deneddylating enzyme Csn5. <b>2016</b> , 31, 1632-7	11
582	Opportunity Knocks: Organic Chemistry for Fragment-Based Drug Discovery (FBDD). <b>2016</b> , 55, 488-92	122
581	Computational analysis of EBNA1 "druggability" suggests novel insights for Epstein-Barr virus inhibitor design. <b>2016</b> , 30, 285-303	24
580	50years of oral lipid-based formulations: Provenance, progress and future perspectives. <b>2016</b> , 101, 167-194	229
579	The discovery and the structural basis of an imidazo[4,5-b]pyridine-based p21-activated kinase 4 inhibitor. <b>2016</b> , 26, 2580-3	10
578	The forgotten or underestimated relevance of biopharmaceutical-based assessments for the oral absorption studies of oxime reactivators. <b>2016</b> , 12, 743-52	2
577	Counting on natural products for drug design. <b>2016</b> , 8, 531-41	592
576	Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia. <b>2016</b> , 59, 8189-206	134
575	An improved model for fragment-based lead generation at AstraZeneca. <i>Drug Discovery Today</i> , <b>2016</b> , 21, 1272-83	8.8 48
574	Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening. <b>2016</b> , 59, 5542-54	15



573	Partially Saturated Bicyclic Heteroaromatics as an sp(3) -Enriched Fragment Collection. <b>2016</b> , 55, 12479-83	45
572	Fragment-Based Drug Design Facilitated by Protein-Templated Click Chemistry: Fragment Linking and Optimization of Inhibitors of the Aspartic Protease Endothiapepsin. <b>2016</b> , 22, 14826-14830	11
571	No Denying It: Medicinal Chemistry Training Is in Big Trouble. <b>2016</b> , 59, 10859-10864	21
570	Active Site Mapping of an Aspartic Protease by Multiple Fragment Crystal Structures: Versatile Warheads To Address a Catalytic Dyad. <b>2016</b> , 59, 9743-9759	9
569	Melting Point Distribution Analysis of Globally Approved and Discontinued Drugs: A Research for Improving the Chance of Success of Drug Design and Discovery. <b>2016</b> , 5, 357-68	13
568	Getting the most out of PubChem for virtual screening. <b>2016</b> , 11, 843-55	59
567	Ligand Efficiency Metrics and their Use in Fragment Optimizations. <b>2016</b> , 75-98	1
566	Strategies for Fragment Library Design. <b>2016</b> , 99-118	1
565	Computational Methods to Support Fragment-based Drug Discovery. <b>2016</b> , 197-222	4
564	Discovery of Inhibitors of Protein-Protein Interactions Using Fragment-Based Methods. <b>2016</b> , 371-390	2
563	An Integrated Approach for Fragment-Based Lead Discovery: Virtual, NMR, and High-Throughput Screening Combined with Structure-Guided Design. Application to the Aspartyl Protease Renin.. <b>2016</b> , 447-486	2
562	Considerations of Protein Subpockets in Fragment-Based Drug Design. <b>2016</b> , 87, 5-20	8
561	Non-competitive inhibitor of nucleoside hydrolase from Leishmania donovani identified by fragment-based drug discovery. <b>2016</b> , 6, 87738-87744	5
560	Identification of Small Molecular Inhibitors for Efflux Protein: DrrA of Mycobacterium tuberculosis. <b>2016</b> , 9, 190-202	6
559	High-Content Screening with a Special Emphasis on Cytotoxicity and Cell Health Measurements. <b>2016</b> , 396-413	
558	Partially Saturated Bicyclic Heteroaromatics as an sp <sup>3</sup> -Enriched Fragment Collection. <b>2016</b> , 128, 12667-12671	14
557	Enumeration of Chemical Fragment Space. <b>2016</b> , 57-74	1
556	Different Roles of Carboxylic Functions in Pharmaceuticals and Agrochemicals. <b>2016</b> , 1-11	4

555	The ways and means of fragment-based drug design. <b>2016</b> , 167, 28-37	45
554	Elaboration of tetra-orthogonally-substituted aromatic scaffolds towards novel EGFR-kinase inhibitors. <b>2016</b> , 14, 8246-52	5
553	The Role of Fragment-based Discovery in Lead Finding. <b>2016</b> , 1-36	3
552	Twenty years on: the impact of fragments on drug discovery. <b>2016</b> , 15, 605-619	505
551	Homology modeling and virtual screening studies of FGF-7 protein-a structure-based approach to design new molecules against tumor angiogenesis. <b>2016</b> , 9, 69-78	10
550	Fragment Screening of ROR $\beta$ Using Cocktail Crystallography: Identification of Simultaneous Binding of Multiple Fragments. <b>2016</b> , 11, 1881-5	5
549	The Many Facets of Screening Library Design. <b>2016</b> , 345-364	1
548	MayaChemTools: An Open Source Package for Computational Drug Discovery. <b>2016</b> , 56, 2292-2297	37
547	Putative histidine kinase inhibitors with antibacterial effect against multi-drug resistant clinical isolates identified by in vitro and in silico screens. <b>2016</b> , 6, 26085	25
546	An Enantio- and Diastereoselective Chemoenzymatic Synthesis of $\beta$ -Fluoro $\beta$ -Hydroxy Carboxylic Esters. <b>2016</b> , 55, 6767-70	26
545	NMR Fragment Screening Hit Induces Plasticity of BRD7/9 Bromodomains. <b>2016</b> , 17, 1456-63	15
544	Computer-Aided Drug Discovery. <b>2016</b> ,	10
543	Microwave-assisted synthesis of functionalized spirohydantoin as 3-D privileged fragments for scouting the chemical space. <b>2016</b> , 57, 2888-2894	20
542	Lead Properties. <b>2016</b> , 283-289	4
541	ACFIS: a web server for fragment-based drug discovery. <b>2016</b> , 44, W550-6	69
540	Introduction: Learnings from the Past [Characteristics of Successful Leads. <b>2016</b> , 1-12	
539	An Enantio- and Diastereoselective Chemoenzymatic Synthesis of $\beta$ -Fluoro $\beta$ -Hydroxy Carboxylic Esters. <b>2016</b> , 128, 6879-6882	14
538	Fragment-Based Discovery of 2-Aminoquinazolin-4(3H)-ones As Novel Class Nonpeptidomimetic Inhibitors of the Plasmepsins I, II, and IV. <b>2016</b> , 59, 374-87	47

537	Phthalimido-thiazoles as building blocks and their effects on the growth and morphology of <i>Trypanosoma cruzi</i> . <b>2016</b> , 111, 46-57	25
536	Exploring different strategies for imbalanced ADME data problem: case study on Caco-2 permeability modeling. <b>2016</b> , 20, 93-109	10
535	New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents. <b>2016</b> , 115, 41-52	9
534	Organische Chemie für die fragmentbasierte Wirkstoffentwicklung (FBDD). <b>2016</b> , 128, 498-503	31
533	Synthesis of two heteroaromatic rings of the future for applications in medicinal chemistry. <b>2016</b> , 6, 22777-22780	6
532	Salicylates are interference compounds in TR-FRET assays. <b>2016</b> , 26, 973-977	9
531	Molecular inflation, attrition and the rule of five. <b>2016</b> , 101, 22-33	116
530	Chemical Space of DNA-Encoded Libraries. <b>2016</b> , 59, 6629-44	171
529	Computational prediction of formulation strategies for beyond-rule-of-5 compounds. <b>2016</b> , 101, 6-21	92
528	Design and synthesis of dihydroisoquinolones for fragment-based drug discovery (FBDD). <b>2016</b> , 14, 1599-610	34
527	Identification of <i>B. anthracis</i> N(5)-carboxyaminoimidazole ribonucleotide mutase (PurE) active site binding compounds via fragment library screening. <b>2016</b> , 24, 596-605	4
526	A new paradigm for navigating compound property related drug attrition. <i>Drug Discovery Today</i> , <b>2016</b> , 21, 72-81	8.8 30
525	Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. <b>2016</b> , 59, 2849-78	199
524	Identification of potential glutaminyl cyclase inhibitors from lead-like libraries by in silico and in vitro fragment-based screening. <b>2017</b> , 21, 175-186	10
523	Biofocussed chemoprospecting: An efficient approach for drug discovery. <b>2017</b> , 90, 128-140	2
522	Monomer-to-dimer transition of <i>Brucella</i> type IV secretion system component VirB8 induces conformational changes. <b>2017</b> , 284, 1218-1232	7
521	Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery. <b>2017</b> , 60, 5235-5266	53
520	Thermo-kinetic analysis space expansion for cyclophilin-ligand interactions - identification of a new nonpeptide inhibitor using Biacore T200. <b>2017</b> , 7, 533-549	5

519	Structural Analysis of Chemokine Receptor-Ligand Interactions. <b>2017</b> , 60, 4735-4779	66
518	Identification of New Lead Molecules Against UBE2NL Enzyme for Cancer Therapy. <b>2017</b> , 182, 1497-1517	8
517	Sulfoximines as ATR inhibitors: Analogs of VE-821. <b>2017</b> , 27, 2659-2662	16
516	Do Fragments and Crystallization Additives Bind Similarly to Drug-like Ligands?. <b>2017</b> , 57, 1197-1209	10
515	N-(Hetero)aryl-2-imidazolines: an emerging privileged motif for contemporary drug design. <b>2017</b> , 53, 240-255	10
514	When Does Chemical Elaboration Induce a Ligand To Change Its Binding Mode?. <b>2017</b> , 60, 128-145	27
513	Identification of a novel chalcone derivative that inhibits Notch signaling in T-cell acute lymphoblastic leukemia. <b>2017</b> , 7, 2213	34
512	Bioactive Coumarins and Xanthenes From Calophyllum Genus and Analysis of Their Druglikeness and Toxicological Properties. <b>2017</b> , 53, 277-307	6
511	Lipophilicity and biomimetic properties to support drug discovery. <b>2017</b> , 12, 885-896	48
510	VSPrep: A General KNIME Workflow for the Preparation of Molecules for Virtual Screening. <b>2017</b> , 36, 1700023	16
509	Human melanoma inhibitory protein binds to the FN12-14 Hep II domain of fibronectin. <b>2017</b> , 12, 02D415	2
508	Structure-based design of novel combinatorially generated NBTIs as potential DNA gyrase inhibitors against various Staphylococcus aureus mutant strains. <b>2017</b> , 13, 1406-1420	8
507	Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases. <b>2017</b> , 90, 1067-1078	13
506	Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes. <b>2017</b> , 60, 5209-5215	8
505	Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5. <b>2017</b> , 19, 1235-1248	20
504	Fragment Database FDB-17. <b>2017</b> , 57, 700-709	42
503	Structure-Based Discovery of Small Molecules Binding to RNA. <b>2017</b> , 47-77	4
502	Targeting the ubiquitin-conjugating enzyme E2D4 for cancer drug discovery-a structure-based approach. <b>2017</b> , 10, 51-67	5

501	Combining Molecular Scaffolds from FDA Approved Drugs: Application to Drug Discovery. <b>2017</b> , 60, 1638-1647	36
500	Global vision of druggability issues: applications and perspectives. <i>Drug Discovery Today</i> , <b>2017</b> , 22, 404-488	45
499	High-Throughput Screening. <b>2017</b> , 50, 149-195	12
498	Fragment-based approach to identify IDO1 inhibitor building blocks. <b>2017</b> , 141, 169-177	13
497	Synthesis and Demonstration of the Biological Relevance of sp <sup>2</sup> -rich Scaffolds Distantly Related to Natural Product Frameworks. <b>2017</b> , 23, 15227-15232	38
496	Integrating computational methods to predict mutagenicity of aromatic azo compounds. <b>2017</b> , 35, 239-257	6
495	Applications of Computer-Aided Drug Design. <b>2017</b> , 1-7	2
494	Ligand efficiency metrics in drug discovery: the pros and cons from a practical perspective. <b>2017</b> , 12, 1087-1104	50
493	Identification of small molecular ligands as potent inhibitors of fatty acid metabolism in <i>Mycobacterium tuberculosis</i> . <b>2017</b> , 1150, 227-241	7
492	Assembly of Fragment Screening Libraries. <b>2017</b> , 263-283	
491	Divergent Synthesis of Cyclopropane-Containing Lead-Like Compounds, Fragments and Building Blocks through a Cobalt Catalyzed Cyclopropanation of Phenyl Vinyl Sulfide. <b>2017</b> , 2017, 5015-5024	25
490	A Bioinorganic Approach to Fragment-Based Drug Discovery Targeting Metalloenzymes. <b>2017</b> , 50, 2007-2016	28
489	In silico structure-based approaches to discover protein-protein interaction-targeting drugs. <b>2017</b> , 131, 22-32	44
488	Supramolecular architecture of 5-bromo-7-methoxy-1-methyl-1H-benzimidazole.3H <sub>2</sub> O: Synthesis, spectroscopic investigations, DFT computation, MD simulations and docking studies. <b>2017</b> , 1149, 602-612	7
487	A Homogeneous Cell-Based Halide-Sensitive Yellow Fluorescence Protein Assay to Identify Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Ion Channel. <b>2017</b> , 15, 395-406	5
486	Pushing the Limits of Detection of Weak Binding Using Fragment-Based Drug Discovery: Identification of New Cyclophilin Binders. <b>2017</b> , 429, 2556-2570	9
485	Fragment-to-Lead Medicinal Chemistry Publications in 2015. <b>2017</b> , 60, 89-99	36
484	DMFC (3,5-dimethyl-1H-furo[3,2-g]chromen-7-one) regulates Bim to trigger Bax and Bak activation to suppress drug-resistant human hepatoma. <b>2017</b> , 22, 381-392	5

483	Molecular property diagnostic suite (MPDS): Development of disease-specific open source web portals for drug discovery. <b>2017</b> , 28, 913-926	4
482	Novel dihydropyrimidine derivatives as potential HDAC inhibitors: in silico study. <b>2017</b> , 5, 10	2
481	Fragment-Based Lead Discovery. <b>2017</b> , 371-439	9
480	Kinetics, Thermodynamics, and Ligand Efficiency Metrics in Drug Discovery. <b>2017</b> , 180-211	1
479	Gentle, fast and effective crystal soaking by acoustic dispensing. <b>2017</b> , 73, 246-255	52
478	Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. <b>2017</b> , 8, 155	14
477	Fragment-based drug discovery and its application to challenging drug targets. <b>2017</b> , 61, 475-484	37
476	Leishmania infantum 5'-Methylthioadenosine Phosphorylase presents relevant structural divergence to constitute a potential drug target. <b>2017</b> , 17, 9	1
475	Small-Molecule Inhibitors of Protein-Protein Interactions. <b>2017</b> , 329-353	2
474	Protein crystallography and drug discovery: recollections of knowledge exchange between academia and industry. <b>2017</b> , 4, 308-321	48
473	Design of high-quality compound library and open innovation. <b>2017</b> , 149, 180-185	
472	Current perspectives in fragment-based lead discovery (FBLD). <b>2017</b> , 61, 453-464	89
471	Fragment-Based Drug Design by NMR. <b>2017</b> , 741-749	
470	Privileged Structures and Motifs (Synthetic and Natural Scaffolds). <b>2017</b> , 116-152	
469	Fragment-Based Drug Design: Strategic Advances and Lessons Learned. <b>2017</b> , 212-232	5
468	Predicting Target and Chemical Druggability. <b>2017</b> , 429-439	2
467	High-Throughput Kinetic Analysis for Target-Directed Covalent Ligand Discovery. <b>2018</b> , 57, 5257-5261	42
466	High-Throughput Kinetic Analysis for Target-Directed Covalent Ligand Discovery. <b>2018</b> , 130, 5355-5359	5

465	Novel carbamate derivatives as selective butyrylcholinesterase inhibitors. <b>2018</b> , 78, 29-38		10
464	Efficient glycosylation of natural Danshensu and its enantiomer by sugar and 2-deoxy sugar donors. <b>2018</b> , 460, 19-28		
463	Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications. <b>2018</b> , 20, 59		41
462	A Fragment Library Screening Approach to Identify Selective Inhibitors against an Essential Fungal Enzyme. <b>2018</b> , 23, 520-531		5
461	Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. <b>2018</b> , 61, 6421-6467		48
460	Fragment-Based Screening of a Natural Product Library against 62 Potential Malaria Drug Targets Employing Native Mass Spectrometry. <b>2018</b> , 4, 431-444		37
459	Identification of small molecular inhibitors for efflux protein Rv2688c of Mycobacterium tuberculosis. <b>2018</b> , 65, 608-621		1
458	A focused fragment library targeting the antibiotic resistance enzyme - Oxacillinase-48: Synthesis, structural evaluation and inhibitor design. <b>2018</b> , 145, 634-648		24
457	Present drug-likeness filters in medicinal chemistry during the hit and lead optimization process: how far can they be simplified?. <i>Drug Discovery Today</i> , <b>2018</b> , 23, 605-615	8.8	53
456	Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain - A fragment based approach. <b>2018</b> , 28, 1708-1713		8
455	Chemical Diversity in the G Protein-Coupled Receptor Superfamily. <b>2018</b> , 39, 494-512		54
454	New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2). <b>2018</b> , 118, 67-79		11
453	Fragment Screening of Human Kynurenine Aminotransferase-II. <b>2018</b> , 23, 511-519		
452	Can we accelerate medicinal chemistry by augmenting the chemist with Big Data and artificial intelligence?. <i>Drug Discovery Today</i> , <b>2018</b> , 23, 1373-1384	8.8	20
451	Structural Evaluation and Binding Mode Analysis of CCL19 and CCR7 Proteins-Identification of Novel Leads for Rheumatic and Autoimmune Diseases: An Insilico study. <b>2018</b> , 10, 346-366		4
450	Discovery of new potent molecular entities able to inhibit mPGES-1. <b>2018</b> , 143, 1419-1427		19
449	Medicinal chemistry in drug discovery in big pharma: past, present and future. <i>Drug Discovery Today</i> , <b>2018</b> , 23, 219-234	8.8	41
448	Synthesis, characterization and computational study of the newly synthesized sulfonamide molecule. <b>2018</b> , 1153, 212-229		22

447	Harnessing the Properties of Natural Products. <b>2018</b> , 58, 451-470	47
446	Computational Nanotechnology: A Tool for Screening Therapeutic Nanomaterials Against Alzheimer's Disease. <b>2018</b> , 613-635	
445	Identification of two antiviral inhibitors targeting 3C-like serine/3C-like protease of porcine reproductive and respiratory syndrome virus and porcine epidemic diarrhea virus. <b>2018</b> , 213, 114-122	13
444	Development and Validation of 2D Difference Intensity Analysis for Chemical Library Screening by Protein-Detected NMR Spectroscopy. <b>2018</b> , 19, 448-458	3
443	Fragment-Based Drug Discovery of Phosphodiesterase Inhibitors. <b>2018</b> , 61, 1415-1424	14
442	The Development of Pharmacophore Modeling: Generation and Recent Applications in Drug Discovery. <b>2018</b> , 24, 3424-3439	19
441	When Humans Met Superbugs: Strategies to Tackle Bacterial Resistances to Antibiotics. <b>2018</b> , 9, 216-226	15
440	Design of a Fragment-Screening Library. <b>2018</b> , 610, 97-115	4
439	Step IIIb: The Drug-Like Chemical Diversity Pool: Diverse and Targeted Compound Collections. <b>2018</b> , 115-177	
438	Imaginative Order from Reasonable Chaos: Conformation-Driven Activity and Reactivity in Exploring Protein-Ligand Interactions. <b>2018</b> , 71, 917	
437	Drug discovery of anticancer drugs targeting methylenetetrahydrofolate dehydrogenase 2. <b>2018</b> , 4, e01021	15
436	Strategies towards expansion of chemical space of natural product-based compounds to enable drug discovery. <b>2018</b> , 54,	0
435	Identification of natural products as an inhibitor of EDG pocket binder of dengue virus envelope protein using fragment-based drug design and molecular docking approach. <b>2018</b> ,	2
434	In silico identification and experimental validation of hits active against KPC-2 $\beta$ -lactamase. <b>2018</b> , 13, e0203241	5
433	Recent Applications of Diversity-Oriented Synthesis Toward Novel, 3-Dimensional Fragment Collections. <b>2018</b> , 6, 460	37
432	Bioinformatics: Sequences, Structures, Phylogeny. <b>2018</b> ,	
431	Structural Bioinformatics: Life Through The 3D Glasses. <b>2018</b> , 191-253	
430	Hit-to-Lead: Hit Validation and Assessment. <b>2018</b> , 610, 265-309	8



429	Diversity-Oriented Synthesis and Chemoinformatic Analysis of the Molecular Diversity of sp-Rich Morpholine Peptidomimetics. <b>2018</b> , 6, 522	15
428	In silico fragment-mapping method: a new tool for fragment-based/structure-based drug discovery. <b>2018</b> , 32, 1229-1245	8
427	Diversity-oriented synthesis of N,N-dimethylamino-substituted azoles employing TBTU. <b>2018</b> , 59, 2732-2735	3
426	Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition. <b>2018</b> , 26, 3021-3029	6
425	Coumarin-Based Molecules as Suitable Models for Developing New Neuroprotective Agents Through Structural Modification. <b>2018</b> , 149-235	2
424	Hot Spot-Based Design of Small-Molecule Inhibitors for Protein-Protein Interactions. <b>2018</b> , 53-71	0
423	Targeting Protein-Protein Interactions by Small Molecules. <b>2018</b> ,	5
422	Fragment-Based Drug Discovery for Developing Inhibitors of Protein-Protein Interactions. <b>2018</b> , 135-176	
421	Early Probe and Drug Discovery in Academia: A Minireview. <b>2018</b> , 7,	22
420	The Impact of Lipophilicity in Drug Discovery: Rapid Measurements by Means of Reversed-Phase HPLC. <b>2018</b> , 1824, 217-228	6
419	Lead-like Drugs: A Perspective. <b>2018</b> , 61, 10375-10384	29
418	Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery. <b>2018</b> , 19,	380
417	Current NMR Techniques for Structure-Based Drug Discovery. <b>2018</b> , 23,	61
416	NMR-Fragment Based Virtual Screening: A Brief Overview. <b>2018</b> , 23,	28
415	Synthesis of Structurally Diverse N-Substituted Quaternary-Carbon-Containing Small Molecules from $\alpha,\beta$ -Disubstituted Propargyl Amino Esters. <b>2018</b> , 24, 13681-13687	21
414	Isosteres of hydroxypyridinethione as drug-like pharmacophores for metalloenzyme inhibition. <b>2018</b> , 23, 1129-1138	13
413	Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119. <b>2018</b> , 16, 278-288	4
412	Synthesis and spectroscopic study of three new oxadiazole derivatives with detailed computational evaluation of their reactivity and pharmaceutical potential. <b>2018</b> , 1173, 469-480	70

411	Challenges with multi-objective QSAR in drug discovery. <b>2018</b> , 13, 851-859	14
410	Novel Inhibitors of T315I Mutant BCR-ABL1 Tyrosine Kinase for Chronic Myeloid Leukemia Disease Through Fragment-Based Drug Design. <b>2018</b> , 185-190	1
409	Novel non-ATP competitive small molecules targeting the CK2 $\beta/\gamma$ interface. <b>2018</b> , 26, 3016-3020	24
408	Generation of Polar Semi-Saturated Bicyclic Pyrazoles for Fragment-Based Drug-Discovery Campaigns. <b>2018</b> , 24, 10443-10451	6
407	Prediction of Medicinal Properties Using Mathematical Models and Computation, and Selection of Plant Materials. <b>2018</b> , 43-73	6
406	Applications of Reactive Cysteine Profiling. <b>2019</b> , 420, 375-417	18
405	A Fragment-Based Approach for the Development of G-Quadruplex Ligands: Role of the Amidoxime Moiety. <b>2018</b> , 23,	5
404	Structural Insights on Fragment Binding Mode Conservation. <b>2018</b> , 61, 5963-5973	14
403	Small Molecule Drug Design. <b>2019</b> , 741-760	6
402	How Size Matters: Diversity for Fragment Library Design. <b>2019</b> , 24,	9
401	Systematic approach for enrichment of docking outcome using consensus scoring functions. <b>2019</b> , 1228, 012019	2
400	Cycloaddition Strategies for the Synthesis of Diverse Heterocyclic Spirocycles for Fragment-Based Drug Discovery. <b>2019</b> , 2019, 5219-5229	17
399	Set-up and screening of a fragment library targeting the 14-3-3 protein interface. <b>2019</b> , 10, 1796-1802	14
398	In silico probing exercises, bioactive-conformational and dynamic simulations strategies for designing and promoting selective therapeutics against Helicobacter pylori strains. <b>2019</b> , 92, 167-179	4
397	Interrogating the Essential Bacterial Cell Division Protein FtsQ with Fragments Using Target Immobilized NMR Screening (TINS). <b>2019</b> , 20,	2
396	Shortcuts to schistosomiasis drug discovery: The state-of-the-art. <b>2019</b> , 139-180	2
395	FlavoDb: a web-based chemical repository of flavonoid compounds. <b>2019</b> , 9, 431	3
394	Protein Allostery in Drug Discovery. <b>2019</b> ,	5

393	Designing DNA Encoded Libraries of Diverse Products in a Focused Property Space. <b>2019</b> , 59, 4645-4653	20
392	TDR Targets 6: driving drug discovery for human pathogens through intensive chemogenomic data integration. <b>2020</b> , 48, D992-D1005	18
391	Chemical Patterns of Proteasome Inhibitors: Lessons Learned from Two Decades of Drug Design. <b>2019</b> , 20,	5
390	HFIP-Promoted de Novo Synthesis of Biologically Relevant Nonnatural $\beta$ -Arylated Amino Esters and Dipeptide Mimetics. <b>2019</b> , 25, 16528	5
389	Fraction Lipophilicity Index (FLI). A drug-like metric for orally administered ionizable drugs. <b>2019</b> , 30, 643-653	1
388	Amino-carboxamide benzothiazoles as potential LSD1 hit inhibitors. Part I: Computational fragment-based drug design. <b>2019</b> , 93, 107440	6
387	Extending the Detection Limit in Fragment Screening of Proteins Using Reverse Micelle Encapsulation. <b>2019</b> , 14, 2224-2232	5
386	A Free Web-Based Protocol to Assist Structure-Based Virtual Screening Experiments. <b>2019</b> , 20,	10
385	A practical asymmetric synthesis of ortho-substituted 4-pyrazolyl-2-ethylamines. <b>2019</b> , 60, 151229	2
384	Key Topics in Molecular Docking for Drug Design. <b>2019</b> , 20,	84
383	The nature of ligand efficiency. <b>2019</b> , 11, 8	28
382	Embracing the Diversity of Halogen Bonding Motifs in Fragment-Based Drug Discovery-Construction of a Diversity-Optimized Halogen-Enriched Fragment Library. <b>2019</b> , 7, 9	21
381	Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening. <b>2019</b> , 47, 10134-10150	18
380	Molecular structure, optoelectronic properties, spectroscopic (FT-IR, FT-Raman and UV-Vis), H-BDE, NBO and drug likeness investigations on 7, 8-benzocoumarin-4-acetic acid (7BAA). <b>2019</b> , 1195, 815-826	17
379	Fragment-based drug design of nature-inspired compounds. <b>2019</b> , 4,	2
378	Fragment-Based Discovery of Novel Potent Sepiapterin Reductase Inhibitors. <b>2019</b> , 62, 6391-6397	10
377	Exploring the Chemical Space of Cytochrome P450 Inhibitors Using Integrated Physicochemical Parameters, Drug Efficiency Metrics and Decision Tree Models. <b>2019</b> , 7, 26	3
376	Identifying Novel Anti-Osteoporosis Leads with a Chemotype-Assembly Approach. <b>2019</b> , 62, 5885-5900	8

375	Spirocycles as Rigidified sp-Rich Scaffolds for a Fragment Collection. <b>2019</b> , 21, 4600-4604		20
374	Computational evaluation of the reactivity and pharmaceutical potential of an organic amine: A DFT, molecular dynamics simulations and molecular docking approach. <b>2019</b> , 222, 117188		31
373	Medicinal Chemistry Aware Database GDBMedChem. <b>2019</b> , 38, e1900031		8
372	Fraction Lipophilicity Index (FLI). <b>2019</b> , 4, 41-66		
371	Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening. <b>2019</b> , 141, 8951-8968		117
370	Inhibition of autotransporter biogenesis by small molecules. <b>2019</b> , 112, 81-98		11
369	Discovery of Novel Alpha-Amylase Inhibitors for Type II Diabetes Mellitus Through the Fragment-Based Drug Design. <b>2019</b> , 25-35		
368	Characterization of Drug-like Chemical Space for Cytotoxic Marine Metabolites Using Multivariate Methods. <b>2019</b> , 4, 5402-5411		8
367	Reactive-cysteine profiling for drug discovery. <b>2019</b> , 50, 29-36		53
366	Crystallographic screening using ultra-low-molecular-weight ligands to guide drug design. <i>Drug Discovery Today</i> , <b>2019</b> , 24, 1081-1086	8.8	37
365	Fragment Hits: What do They Look Like and How do They Bind?. <b>2019</b> , 62, 3381-3394		33
364	Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer. <b>2019</b> , 62, 4120-4130		8
363	Clinical candidates modulating protein-protein interactions: The fragment-based experience. <b>2019</b> , 167, 76-95		15
362	Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis. <b>2019</b> , 29, 974-977		9
361	Synthesis and Biological Evaluation of Polyfluoroalkylated Antipyridines and their Isomeric O-Methylpyrazoles. <b>2019</b> , 15, 521-536		7
360	Benford's law in medicinal chemistry: Implications for drug design. <b>2019</b> , 11, 2247-2253		4
359	Spectroscopic, antimicrobial and computational study of novel benzoxazole derivative. <b>2019</b> , 1176, 881-894		14
358	Synthesis, spectroscopic characterization, reactive properties by DFT calculations, molecular dynamics simulations and biological evaluation of Schiff bases tethered 1,2,4-triazole and pyrazole rings. <b>2019</b> , 1177, 47-54		44

357	The herbicide quinclorac as potent lipase inhibitor: Discovery via virtual screening and in vitro/in vivo validation. <b>2019</b> , 93, 787-797	8
356	Novel Pyoverdine Inhibitors Mitigate Pathogenesis. <b>2018</b> , 9, 3317	29
355	Smart Design of Small-Molecule Libraries: When Organic Synthesis Meets Cheminformatics. <b>2019</b> , 20, 1115-1123	7
354	Diversity-oriented synthesis of bicyclic fragments containing privileged azines. <b>2019</b> , 29, 248-251	8
353	Ligand-based design, synthesis and biological evaluation of xanthine derivatives as LSD1/KDM1A inhibitors. <b>2019</b> , 162, 555-567	15
352	Synthesis and spectroscopic study of two new pyrazole derivatives with detailed computational evaluation of their reactivity and pharmaceutical potential. <b>2019</b> , 1181, 599-612	44
351	NMR screening and studies of target-ligand interactions. <b>2019</b> , 88, 59-98	6
350	Substance-Based Bibliometrics: Identifying Research Gaps by Counting and Analyzing Substances. <b>2019</b> , 4, 86-94	4
349	In Silico Structure-Based Prediction of Receptor-ligand Binding Affinity: Current Progress and Challenges. <b>2019</b> , 109-175	2
348	Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1. <b>2019</b> , 161, 479-492	11
347	Evolution of commercially available compounds for HTS. <i>Drug Discovery Today</i> , <b>2019</b> , 24, 390-402	8.8 27
346	Applications of Metabolic Phenotyping in Pharmaceutical Research and Development. <b>2019</b> , 407-447	1
345	A Continuous Flow Strategy for the Facile Synthesis and Elaboration of Semi-Saturated Heterobicyclic Fragments. <b>2019</b> , 2019, 1341-1349	5
344	NAOMInext - Synthetically feasible fragment growing in a structure-based design context. <b>2019</b> , 163, 747-762	4
343	Discovery and Characterization of Two Classes of Selective Inhibitors of the Suppressor of the TCR Signaling Family of Proteins. <b>2019</b> , 5, 250-259	2
342	Ligand-Based Fluorine NMR Screening: Principles and Applications in Drug Discovery Projects. <b>2019</b> , 62, 2218-2244	72
341	Structural, spectroscopic characterization of 2-(5-methyl-1-benzofuran-3-yl) acetic acid in monomer, dimer and identification of specific reactive, drug likeness properties: Experimental and computational study. <b>2019</b> , 1178, 1-17	25
340	Computational fragment-based design of Wee1 kinase inhibitors with tricyclic core scaffolds. <b>2019</b> , 30, 213-226	2

339	Quinoline derivatives as possible lead compounds for anti-malarial drugs: Spectroscopic, DFT and MD study. <b>2020</b> , 13, 632-648	71
338	Discovery of new potential triplet acting inhibitor for Alzheimer's disease via X-ray crystallography, molecular docking and molecular dynamics. <b>2020</b> , 38, 1903-1917	5
337	Plant natural fragments, an innovative approach for drug discovery. <b>2020</b> , 19, 1141-1156	4
336	Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R). <b>2020</b> , 63, 2292-2307	9
335	Structure-based design of selective histone deacetylase 6 zinc binding groups. <b>2020</b> , 38, 3166-3177	5
334	Exploring the detailed spectroscopic characteristics, chemical and biological activity of two cyanopyrazine-2-carboxamide derivatives using experimental and theoretical tools. <b>2020</b> , 224, 117414	53
333	The 3F Library: Fluorinated Fsp3-Rich Fragments for Expeditious 19F NMR Based Screening. <b>2020</b> , 132, 2224-2230	6
332	Development of a Web-Based Laboratory Class to Reduce the Challenges in Teaching Fragment-Based Drug Design. <b>2020</b> , 97, 427-436	9
331	In Silico Design and Analysis of a Kinase-Focused Combinatorial Library Considering Diversity and Quality. <b>2020</b> , 60, 92-107	2
330	Dose Predictions for Drug Design. <b>2020</b> , 63, 6423-6435	18
329	Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery. <b>2020</b> , 63, 1156-1177	12
328	Interaction Energetics and Druggability of the Protein-Protein Interaction between Kelch-like ECH-Associated Protein 1 (KEAP1) and Nuclear Factor Erythroid 2 Like 2 (Nrf2). <b>2020</b> , 59, 563-581	11
327	The 3F Library: Fluorinated Fsp -Rich Fragments for Expeditious F NMR Based Screening. <b>2020</b> , 59, 2204-2210	31
326	Expanding medicinal chemistry into 3D space: metallofragments as 3D scaffolds for fragment-based drug discovery. <b>2019</b> , 11, 1216-1225	51
325	Isoquinolines from national herb Corydalis tomentella and neuroprotective effect against lipopolysaccharide-induced BV2 microglia cells. <b>2020</b> , 95, 103489	5
324	Screening of benzenesulfonamide in combination with chemically diverse fragments against carbonic anhydrase by differential scanning fluorimetry. <b>2020</b> , 35, 306-310	4
323	Fragments as Novel Starting Points for tRNA-Guanine Transglycosylase Inhibitors Found by Alternative Screening Strategies. <b>2020</b> , 15, 324-337	6
322	Kinetic Target-Guided Synthesis: Reaching the Age of Maturity. <b>2020</b> , 63, 3817-3833	11

321	Energy-optimized pharmacophore coupled virtual screening in the discovery of quorum sensing inhibitors of LasR protein of. <b>2020</b> , 38, 5374-5388	14
320	Is it time for biocatalysis in fragment-based drug discovery?. <b>2020</b> , 11, 11104-11112	10
319	Guided by evolution: from biology oriented synthesis to pseudo natural products. <b>2020</b> , 37, 1497-1510	15
318	A Retrospective Biopharmaceutical Analysis of >800 Approved Oral Drug Products: Are Drug Properties of Solid Dispersions and Lipid-Based Formulations Distinctive?. <b>2020</b> , 109, 3248-3261	8
317	(E)-trans-2-phenyl-2,3-dihydrobenzofurans as leishmanicidal agents: Synthesis, in vitro evaluation and SAR analysis. <b>2020</b> , 205, 112493	4
316	Hit/Lead Discovery. <b>2020</b> , 97-131	
315	Pharmacokinetics (ADME). <b>2020</b> , 133-224	
314	Current Challenges and Opportunities in Designing Protein-Protein Interaction Targeted Drugs. <b>2020</b> , 13, 11-25	10
313	Molecular docking studies, molecular dynamics and ADME/tox reveal therapeutic potentials of STOCK1N-69160 against papain-like protease of SARS-CoV-2. <b>2021</b> , 25, 1761-1773	12
312	Molecular Modeling, Synthesis and Biological Evaluation of -Phenyl-4-Hydroxy-6-Methyl-2-Quinolone-3-CarboxAmides as Anticancer Agents. <b>2020</b> , 25,	3
311	SAVI, in silico generation of billions of easily synthesizable compounds through expert-system type rules. <b>2020</b> , 7, 384	6
310	Shape-Based Descriptors for Efficient Structure-Based Fragment Growing. <b>2020</b> , 60, 6269-6281	1
309	Crystal structures of the RNA triphosphatase from provide insights into how it recognizes the 5'-end of the RNA substrate. <b>2020</b> , 295, 9076-9086	1
308	A Photoaffinity-Based Fragment-Screening Platform for Efficient Identification of Protein Ligands. <b>2020</b> , 59, 21096-21105	17
307	Multimodal small-molecule screening for human prion protein binders. <b>2020</b> , 295, 13516-13531	6
306	From Riluzole to Dexamipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies. <b>2020</b> , 25,	6
305	Chemoinformatics-based enumeration of chemical libraries: a tutorial. <b>2020</b> , 12, 64	13
304	In silico approach in the assessment of chromatographic parameters as descriptors of diphenylacetamides biological/pharmacological profile. <b>2020</b> , 43, 852-862	

303	Computer-Aided Analysis of Multiple SARS-CoV-2 Therapeutic Targets: Identification of Potent Molecules from African Medicinal Plants. <b>2020</b> , 2020, 1878410	5
302	Application of Fragment-Based Drug Discovery to Versatile Targets. <b>2020</b> , 7, 180	30
301	A Photoaffinity-Based Fragment-Screening Platform for Efficient Identification of Protein Ligands. <b>2020</b> , 132, 21282-21291	2
300	Targeting the Initiator Protease of the Classical Pathway of Complement Using Fragment-Based Drug Discovery. <b>2020</b> , 25,	2
299	LEADS-FRAG: A Benchmark Data Set for Assessment of Fragment Docking Performance. <b>2020</b> , 60, 6544-6554	3
298	Study on reversal of ABCB1 mediated multidrug resistance in Colon cancer by acetogenins: An - approach. <b>2020</b> , 1-12	7
297	KinFragLib: Exploring the Kinase Inhibitor Space Using Subpocket-Focused Fragmentation and Recombination. <b>2020</b> , 60, 6081-6094	7
296	Quantitative Prediction of Hemolytic Toxicity for Small Molecules and Their Potential Hemolytic Fragments by Machine Learning and Recursive Fragmentation Methods. <b>2020</b> , 60, 3231-3245	5
295	Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank. <b>2020</b> , 287, 3703-3718	25
294	Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker. <b>2020</b> , 38, 1087-1096	29
293	Demonstration of the utility of DOS-derived fragment libraries for rapid hit derivatisation in a multidirectional fashion. <b>2020</b> , 11, 10792-10801	5
292	SG1002 and Catenated Divalent Organic Sulfur Compounds as Promising Hydrogen Sulfide Prodrugs. <b>2020</b> , 33, 1010-1045	16
291	SMILES-based deep generative scaffold decorator for de-novo drug design. <b>2020</b> , 12, 38	45
290	Privileged Scaffold Analysis of Natural Products with Deep Learning-based Indication Prediction Model. <b>2020</b> , 39, e2000057	3
289	Indole moiety induced biological potency in pseudo-peptides derived from 2-amino-2-(1H-indole-2-yl) based acetamides: Chemical synthesis, in vitro anticancer activity and theoretical studies. <b>2020</b> , 1217, 128445	4
288	Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening. <b>2020</b> , 200, 112440	7
287	Fragment Linking Strategies for Structure-Based Drug Design. <b>2020</b> , 63, 11420-11435	20
286	A Computer Vision Approach to Align and Compare Protein Cavities: Application to Fragment-Based Drug Design. <b>2020</b> , 63, 7127-7142	4



285	NMR quality control of fragment libraries for screening. <b>2020</b> , 74, 555-563		8
284	Synthetic approaches toward small molecule libraries. <b>2020</b> , 1-34		1
283	Virtual screening of small-molecule libraries. <b>2020</b> , 103-125		1
282	Identification of potential inhibitors of human methionine aminopeptidase (type II) for cancer therapy: Structure-based virtual screening, ADMET prediction and molecular dynamics studies. <b>2020</b> , 86, 107244		5
281	High throughput in vivo phenotypic screening for drug repurposing: Discovery of MLR-1023 a novel insulin sensitizer and novel Lyn kinase activator with clinical proof of concept. <b>2020</b> , 28, 115425		7
280	Discovery of a novel kinase hinge binder fragment by dynamic undocking. <b>2020</b> , 11, 552-558		6
279	2. Fundamental physical and chemical concepts behind drug-likeness and natural product-likeness <b>2020</b> , 55-80		1
278	Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from. <b>2020</b> , 6, 2192-2201		2
277	Spectroscopic elucidation (FT-IR, FT-Raman and UV-visible) with NBO, NLO, ELF, LOL, drug likeness and molecular docking analysis on 1-(2-ethylsulfonyl-ethyl)-2-methyl-5-nitro-imidazole: An antiprotozoal agent. <b>2020</b> , 88, 107330		17
276	Predicting Hydration Free Energies of the FreeSolv Database of Drug-like Molecules with Molecular Density Functional Theory. <b>2020</b> , 60, 3558-3565		3
275	The rise of molecular simulations in fragment-based drug design (FBDD): an overview. <i>Drug Discovery Today</i> , <b>2020</b> , 25, 1693-1701	8.8	10
274	Rescue of mutant gonadotropin-releasing hormone receptor function independent of cognate receptor activity. <b>2020</b> , 10, 10579		1
273	ChEMBL-Likeness Score and Database GDBChEMBL. <b>2020</b> , 8, 46		14
272	Striking essential oil: tapping into a largely unexplored source for drug discovery. <b>2020</b> , 10, 2867		11
271	Methods for Design of Kinase Inhibitors as Anticancer Drugs. <b>2019</b> , 7, 873		32
270	NMR Studies of Protein-Small Molecule Interactions for Drug Discovery. <b>2020</b> , 325-345		1
269	Impact of Recently Determined Crystallographic Structures of GPCRs on Drug Discovery. <b>2020</b> , 449-477		1
268	Fsp-rich and diverse fragments inspired by natural products as a collection to enhance fragment-based drug discovery. <b>2020</b> , 56, 2280-2283		15

267	Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity. <b>2020</b> , 99, 103797		11
266	Molecular Interactions of Pyrazine-Based Compounds to Proteins. <b>2020</b> , 63, 8901-8916		14
265	Improving the drug-likeness of inspiring natural products - evaluation of the antiparasitic activity against <i>Trypanosoma cruzi</i> through semi-synthetic and simplified analogues of licarin A. <b>2020</b> , 10, 5467		12
264	Multitarget Approach to Drug Candidates against Alzheimer's Disease Related to AChE, SERT, BACE1 and GSK3 $\beta$ Protein Targets. <b>2020</b> , 25,		3
263	Library Design Strategies To Accelerate Fragment-Based Drug Discovery. <b>2020</b> , 26, 11391-11403		10
262	A Proof-of-Concept Fragment Screening of a Hit-Validated 96-Compounds Library against Human Carbonic Anhydrase II. <b>2020</b> , 10,		4
261	Design and Synthesis of 56 Shape-Diverse 3D Fragments. <b>2020</b> , 26, 8969-8975		20
260	Revisiting biomolecular NMR spectroscopy for promoting small-molecule drug discovery. <b>2020</b> , 74, 501-508		4
259	Covalent fragment libraries in drug discovery. <i>Drug Discovery Today</i> , <b>2020</b> , 25, 983-996	8.8	33
258	Structural dynamics and allostery of Rab proteins: strategies for drug discovery and design. <b>2021</b> , 22, 270-287		4
257	E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones. <b>2021</b> , 26, 484-502		48
256	Identification of Compounds That Promote Readthrough of Premature Termination Codons in the CFTR. <b>2021</b> , 26, 205-215		1
255	Clearance prediction for Amgen molecules against Extended Clearance Classification System (ECCS) and future directions. <i>Drug Discovery Today</i> , <b>2021</b> , 26, 10-16	8.8	1
254	Using NMR Spectroscopy in the Fragment-Based Drug Discovery of Small-Molecule Anticancer Targeted Therapies. <b>2021</b> , 16, 725-742		5
253	Tailored Bioorthogonal and Bioconjugate Chemistry: A Source of Inspiration for Developing Kinetic Target-Guided Synthesis Strategies. <b>2021</b> , 32, 63-72		3
252	Identification of Novel Fragments Binding to the PDZ1-2 Domain of PSD-95. <b>2021</b> , 16, 949-954		
251	Chemography: Searching for Hidden Treasures. <b>2021</b> , 61, 179-188		8
250	Analysis of non-structural proteins, NSPs of SARS-CoV-2 as targets for computational drug designing. <b>2021</b> , 25, 100847		15

249	Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage Response. <b>2021</b> , 163, 130-142	8
248	Scopy: an integrated negative design python library for desirable HTS/VS database design. <b>2021</b> , 22,	6
247	Advances in Docking-Based Drug Design for Microbial and Cancer Drug Targets. <b>2021</b> , 407-424	
246	Fragment based drug design: Connecting small substructures for a bioactive lead. <b>2021</b> , 235-253	
245	Pharmacological Target Engagement and Validation. <b>2021</b> ,	
244	Identification of DNA Methyltransferase-1 Inhibitor for Breast Cancer Therapy through Computational Fragment-Based Drug Design. <b>2021</b> , 26,	2
243	Discovery of small molecules targeting the tandem tudor domain of the epigenetic factor UHRF1 using fragment-based ligand discovery. <b>2021</b> , 11, 1121	8
242	Fragment dissolved molecular dynamics: a systematic and efficient method to locate binding sites. <b>2021</b> , 23, 3123-3134	2
241	Specificity of Molecular Fragments Binding to S100B versus S100A1 as Identified by NMR and Site Identification by Ligand Competitive Saturation (SILCS). <b>2021</b> , 26,	2
240	Targeting protein-protein interactions in the DNA damage response pathways for cancer chemotherapy. <b>2021</b> , 2, 1167-1195	2
239	Emergent synthetic methods for the modular advancement of sp-rich fragments. <b>2021</b> , 12, 4646-4660	15
238	A direct-to-biology high-throughput chemistry approach to reactive fragment screening. <b>2021</b> , 12, 12098-12106	
237	The ADME Encyclopedia. <b>2021</b> , 1-7	
236	Fragment-Based Drug Design of Selective HDAC6 Inhibitors. <b>2021</b> , 2266, 155-170	0
235	Virtual Libraries for Docking Methods: Guidelines for the Selection and the Preparation. <b>2021</b> , 99-117	0
234	Drug Lead Optimization. <b>2021</b> ,	
233	Transmol: repurposing a language model for molecular generation.. <b>2021</b> , 11, 25921-25932	0
232	Drug Repositioning: Principles, Resources, and Application of Structure-Based Virtual Screening for the Identification of Anticancer Agents. <b>2021</b> , 313-336	2

231	Discovery of drug-like acetylcholinesterase inhibitors by rapid virtual screening of a 6.9million compound database. <b>2021</b> , 97, 1048-1058		2
230	Discovering High Potent Hsp90 Inhibitors as Antinosopharyngeal Carcinoma Agents through Fragment Assembling Approach. <b>2021</b> , 64, 2010-2023		4
229	In Silico Therapeutic Peptide Design Against Pathogenic Domain Swapped Human Cystatin C Dimer. <b>2021</b> , 27, 1555-1575		1
228	Natural product fragment combination to performance-diverse pseudo-natural products. <b>2021</b> , 12, 1883		10
227	What makes a good fragment in fragment-based drug discovery?. <b>2021</b> , 16, 723-726		4
226	Hydroxypyridinethione Inhibitors of Human Insulin-Degrading Enzyme. <b>2021</b> , 16, 1775-1787		2
225	ADMET In Vitro Profiling Utility and Applications in Lead Discovery. 1-31		0
224	Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist S6 Stimulates Insulin Secretion From Rat Islets. <b>2021</b> , 12, 664802		
223	Evaluating and evolving a screening library in academia: the St Jude approach. <i>Drug Discovery Today</i> , <b>2021</b> , 26, 1060-1069	8.8	5
222	Site-directed Fragnomics and MD Simulations Approaches to Identify Interleukin-2 Inhibitors. <b>2021</b> , 17, 407-417		
221	Fragment-Based Lead Discovery. 1-35		
220	Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds. <b>2021</b> , 64, 4623-4661		6
219	Applications of Virtual Screening in Bioprospecting: Facts, Shifts, and Perspectives to Explore the Chemo-Structural Diversity of Natural Products. <b>2021</b> , 9, 662688		10
218	Quantitative Structure-Property Relationship Modelling for the Prediction of Singlet Oxygen Generation by Heavy-Atom-Free BODIPY Photosensitizers*. <b>2021</b> , 27, 9934-9947		8
217	Virtual screening of curcumin analogues as DYRK2 inhibitor: Pharmacophore analysis, molecular docking and dynamics, and ADME prediction. 10, 394		1
216	Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence. <b>2021</b> , 12, 642383		2
215	Introduction of Advanced Methods for Structure-based Drug Discovery. <b>2021</b> , 16, 351-363		6
214	Escape from planarity in fragment-based drug discovery: A physicochemical and 3D property analysis of synthetic 3D fragment libraries.. <b>2020</b> , 38, 77-90		3

213	DMSO Solubility Assessment for Fragment-Based Screening. <b>2021</b> , 26,	2
212	Two Inhibitors Against the 3C-Like Proteases of Swine Coronavirus and Feline Coronavirus. <b>2021</b> , 1	0
211	Metal complexes for therapeutic applications. <b>2021</b> , 3, 523-534	10
210	Inhibitors of Human Divalent Metal Transporters DMT1 (SLC11A2) and ZIP8 (SLC39A8) from a GDB-17 Fragment Library. <b>2021</b> , 16, 3306-3314	4
209	Fragment-Based Drug Discovery for RNA Targets. <b>2021</b> , 16, 2588-2603	0
208	Easy preparation of novel 3,3-dimethyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide: Molecular structure, Hirshfeld surface, NCI analyses and molecular docking on AMPA receptors. <b>2021</b> , 1238, 130435	4
207	Synthesis of a Series of Novel 2-Amino-5-Substituted 1,3,4-oxadiazole and 1,3,4-thiadiazole Derivatives as Potential Anticancer, Antifungal and Antibacterial Agents. <b>2021</b> ,	7
206	Combination of Pseudo-Natural Product Design and Formal Natural Product Ring Distortion Yields Stereochemically and Biologically Diverse Pseudo-Sesquiterpenoid Alkaloids. <b>2021</b> , 133, 21554-21565	2
205	Combination of Pseudo-Natural Product Design and Formal Natural Product Ring Distortion Yields Stereochemically and Biologically Diverse Pseudo-Sesquiterpenoid Alkaloids. <b>2021</b> , 60, 21384-21395	5
204	Structural, antioxidant, antiproliferative and in-silico study of pyridine-based hydrazonyl-selenazoles and their sulphur isosteres. <b>2021</b> , 1240, 130512	5
203	NMR Spectroscopy of the Main Protease of SARS-CoV-2 and Fragment-Based Screening Identify Three Protein Hotspots and an Antiviral Fragment. <b>2021</b> , 133, 25632	0
202	Logistic regression and random forest unveil key molecular descriptors of druglikeness. <b>2021</b> , 21, 39-58	0
201	KRAS G12C fragment screening renders new binding pockets. <b>2021</b> , 1-14	2
200	A proteome-wide atlas of lysine-reactive chemistry. <b>2021</b> , 13, 1081-1092	20
199	NMR Spectroscopy of the Main Protease of SARS-CoV-2 and Fragment-Based Screening Identify Three Protein Hotspots and an Antiviral Fragment. <b>2021</b> , 60, 25428-25435	3
198	Inhibition of Dethiobiotin Synthase (DTBS): Toward Next-Generation Antituberculosis Agents. <b>2021</b> , 16, 2339-2347	0
197	Recent progress in fragment-based drug discovery facilitated by NMR spectroscopy. <b>2021</b> , 100025	0
196	The Role of Natural Products as Sources of Therapeutic Agents for Innovative Drug Discovery. <b>2021</b> ,	3

195	Use of molecular docking computational tools in drug discovery. <b>2021</b> , 60, 273-343	22
194	C-H functionalisation tolerant to polar groups could transform fragment-based drug discovery (FBDD). <b>2021</b> , 12, 11976-11985	13
193	Covalent fragment screening. <b>2021</b> , 56, 243-265	0
192	Application of FMO to Ligand Design: SBDD, FBDD, and Protein-Protein Interaction. <b>2021</b> , 205-251	
191	Key Aspects for Achieving Hits by Virtual Screening Studies. <b>2021</b> , 455-487	2
190	Saturation transfer difference NMR for fragment screening. <b>2013</b> , 5, 251-68	16
189	DEVELOPMENT AND APPLICATIONS OF GLOBAL ADMET MODELS. 245-265	3
188	NMR screening in fragment-based drug design: a practical guide. <b>2015</b> , 1263, 197-208	7
187	Fragment library design: using cheminformatics and expert chemists to fill gaps in existing fragment libraries. <b>2015</b> , 1289, 43-53	4
186	A computational fragment-based de novo design protocol guided by ligand efficiency indices (LEI). <b>2015</b> , 1289, 89-100	3
185	Crystallographic fragment screening. <b>2012</b> , 841, 161-77	12
184	QSAR/QSPR Modeling in the Design of Drug Candidates with Balanced Pharmacodynamic and Pharmacokinetic Properties. <b>2017</b> , 339-384	2
183	Natural Product-Based Drug Discovery in Africa: The Need for Integration into Modern Drug Discovery Paradigms. <b>2012</b> , 101-126	2
182	Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors. <b>2019</b> , 1163, 253-278	10
181	Computational-aided design of a library of lactams through a diversity-oriented synthesis strategy. <b>2020</b> , 28, 115539	5
180	F2X-Universal and F2X-Entry: Structurally Diverse Compound Libraries for Crystallographic Fragment Screening. <b>2020</b> , 28, 694-706.e5	15
179	Structural and Functional Studies of Bacterial Enolase, a Potential Target against Gram-Negative Pathogens. <b>2019</b> , 58, 1188-1197	8
178	Development of Orally Efficacious Allosteric Inhibitors of TNF $\alpha$ via Fragment-Based Drug Design. <b>2021</b> , 64, 417-429	6

177	CHAPTER 1: Different Flavours of Fragments. <b>2015</b> , 1-18	1
176	CHAPTER 4: Current Status and Future Direction of Fragment-Based Drug Discovery: A Computational Chemistry Perspective. <b>2015</b> , 73-100	2
175	CHAPTER 5: Fragment Screening of G Protein-Coupled Receptors. <b>2015</b> , 101-125	1
174	Chapter 2: Chemical Space and the Difference Between Natural Products and Synthetics. <b>2009</b> , 28-43	3
173	Fragments: where are we now?. <b>2020</b> , 48, 271-280	16
172	Trehalose-6-phosphate phosphatase as a broad-spectrum therapeutic target against eukaryotic and prokaryotic pathogens. <b>2017</b> , 1, 675-683	4
171	Novel anti-staphylococcal and anti-biofilm properties of two anti-malarial compounds: MMV665953 {1-(3-chloro-4-fluorophenyl)-3-(3,4-dichlorophenyl)urea} and MMV665807 {5-chloro-2-hydroxy-N-[3-(trifluoromethyl)phenyl]benzamide}. <b>2017</b> , 66, 377-387	1
170	Gentle, fast and effective crystal soaking by acoustic dispensing.	1
169	Multimodal small-molecule screening for human prion protein binders.	1
168	Multiplexed experimental strategies for fragment library screening using SPR biosensors.	1
167	FragMAX: the fragment-screening platform at the MAX IV Laboratory. <b>2020</b> , 76, 771-777	15
166	Exhaustive sampling of the fragment space associated to a molecule leading to the generation of conserved fragments. <b>2018</b> , 91, 655-667	0
165	FMO as a Tool for Structure-Based Drug Design. <b>2009</b> , 217-244	2
164	Fragment-Based Discovery of Irreversible Covalent Inhibitors of Cysteine Proteases Using Chlorofluoroacetamide Library. <b>2020</b> , 68, 1074-1081	3
163	Predicting Allosteric Effects from Orthosteric Binding in Hsp90-Ligand Interactions: Implications for Fragment-Based Drug Design. <b>2016</b> , 12, e1004840	17
162	Discovery of fragment molecules that bind the human peroxiredoxin 5 active site. <b>2010</b> , 5, e9744	17
161	Virtual and biophysical screening targeting the $\beta$ -tubulin complex--a new target for the inhibition of microtubule nucleation. <b>2013</b> , 8, e63908	12
160	Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2. <b>2013</b> , 8, e65689	19

159	Label free fragment screening using surface plasmon resonance as a tool for fragment finding - analyzing parkin, a difficult CNS target. <b>2013</b> , 8, e66879	10
158	Automated NMR fragment based screening identified a novel interface blocker to the LARG/RhoA complex. <b>2014</b> , 9, e88098	16
157	Identification of potential small molecule allosteric modulator sites on IL-1R1 ectodomain using accelerated conformational sampling method. <b>2015</b> , 10, e0118671	22
156	Fundamental physical and chemical concepts behind "Drug-likeness" and "Natural product-likeness" <b>2019</b> , 4,	4
155	Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer. <b>2018</b> , 9, 13139-13153	24
154	Privileged Structures in the Design of Potential Drug Candidates for Neglected Diseases. <b>2019</b> , 26, 4323-4354	20
153	The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization. <b>2019</b> , 26, 3838-3873	17
152	VSPrep: A KNIME Workflow for the Preparation of Molecular Databases for Virtual Screening. <b>2020</b> , 27, 6480-6494	1
151	Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery. <b>2017</b> , 17, 4-15	40
150	Chemical Intuition in Drug Design and Discovery. <b>2019</b> , 19, 1679-1693	3
149	Virtual Screening Techniques in Drug Discovery: Review and Recent Applications. <b>2019</b> , 19, 1751-1767	32
148	Therapeutic Targets and Computational Approaches on Drug Development for COVID-19. <b>2020</b> , 20, 2210-2220	11
147	Consensus Docking in Drug Discovery. <b>2020</b> , 16, 182-190	6
146	Molecular docking based screening of novel designed chalcone series of compounds for their anti-cancer activity targeting EGFR kinase domain. <b>2015</b> , 11, 322-9	19
145	Kinetic Profiling of Ligands and Fragments Binding to GPCRs by TR-FRET. <b>2021</b> , 1-32	
144	Screening of $\alpha$ - and $\beta$ -Adrenergic Receptor Modulators through Advanced Pharmacoinformatics and Machine Learning Approaches. <b>2021</b> , 22,	0
143	Ligand GA: a genetic algorithm for automated protein inhibitor design.	
142	Virtual Ligand Screening: A Method to Discover New Drug Leads. <b>2007</b> , 251-272	



- 141 High-Throughput Screening for Small-Molecule Drug Discovery.
- 140 References. 575-608
- 139 The Chemical Space of Flavours. **2014**, 83-96 2
- 138 CHAPTER 2:High-Throughput Screening. **2014**, 16-41
- 137 Adventures in Small Molecule Fragment Screening by X-ray Crystallography. **2015**, 197-208
- 136 Virtual fragment preparation for computational fragment-based drug design. **2015**, 1289, 31-41
- 135 Integrated in Silico Methods for the Design and Optimization of Novel Drug Candidates. **2015**, 269-317
- 134 Integrated in Silico Methods for the Design and Optimization of Novel Drug Candidates. **2017**, 434-481
- 133 Rise of Virtual Drug Design Tools. **2017**, 1,
- 132 Protein Docking and Drug Design. **2018**, 207-241
- 131 In Silico Identification and Experimental Validation of Novel KPC-2  $\beta$ -Lactamase Inhibitors.
- 130 Rapid covalent-probe discovery by electrophile fragment screening.
- 129 Cheminformatic Analysis of Natural Product Fragments. **2019**, 110, 143-175 0
- 128 Protein Docking and Drug Design. **2019**, 889-922
- 127 Extending the Small Molecule Similarity Principle to All Levels of Biology.
- 126 Extending the small molecule similarity principle to all levels of biology. 1
- 125 CHAPTER 4:Best Practices for Design and Characterization of Covalent Chemical Probes. **2020**, 69-99 0
- 124 Analysis of the uncharted, druglike property space by self-organizing maps. **2021**, 1 0

123	Multi-objective optimization methods in novel drug design. <b>2021</b> , 16, 647-658	4
122	Using a fragment-based approach to identify novel chemical scaffolds targeting the dihydrofolate reductase (DHFR) from <i>Mycobacterium tuberculosis</i> .	
121	Machine Learning Applied to the Modeling of Pharmacological and ADMET Endpoints. <b>2022</b> , 2390, 61-101	1
120	Introduction to Fragment Screening. <b>2007</b> , 49-72	1
119	Fragment-Based Screening by X-ray Crystallography. <b>2007</b> , 99-127	
118	Chemical validation of <i>Mycobacterium tuberculosis</i> phosphopantetheine adenylyltransferase using fragment linking and CRISPR interference.	0
117	Acrylamide Fragment Inhibitors that Induce Unprecedented Conformational Distortions in Enterovirus 71 3C and SARS-CoV-2 Main Protease.	
116	Identification of New Structural Fragments for the Design of Lactate Dehydrogenase A Inhibitors. <b>2016</b> , 8, 118-122	
115	Structure Modeling of Human Tyrosyl-DNA Phosphodiesterase 1 and Screening for Its Inhibitors. <b>2017</b> , 9, 59-66	2
114	Cardiovascular Drugs: an Insight of In Silico Drug Design Tools.	1
113	Unique Diacidic Fragments Inhibit the OXA-48 Carbapenemase and Enhance the Killing of Producing OXA-48. <b>2021</b> , 7, 3345-3354	0
112	Essential oils of $\beta$ chemical composition, bioactivity, docking, and ADMET profiling of selective major compounds. <b>2021</b> ,	1
111	The ADME Encyclopedia. <b>2022</b> , 1-7	
110	THz Technique in Confirming Pharmacological Rules of Thumb. <b>2020</b> ,	
109	New Pharmacokinetic and Microbiological Prediction Equations to Be Used as Models for the Search of Antibacterial Drugs.. <b>2022</b> , 15,	
108	Pyridylpiperazine-based allosteric inhibitors of RND-type multidrug efflux pumps.. <b>2022</b> , 13, 115	2
107	Comprehensive analysis of commercial fragment libraries.. <b>2022</b> , 13, 300-310	1
106	Computational Medicinal Chemistry to Target GPCRs. <b>2022</b> ,	

105	Design, synthesis, antimicrobial evaluations and in silico studies of novel pyrazol-5(4H)-one and 1H-pyrazol-5-ol derivatives. <b>2022</b> , 15, 103682	4
104	Early-stage structure-based drug discovery for small GTPases by NMR spectroscopy.. <b>2022</b> , 236, 108110	0
103	Identification of a small compound that specifically inhibits Zika virus in vitro and in vivo by targeting the NS2B-NS3 protease.. <b>2022</b> , 199, 105255	1
102	In-Silico Analysis of VP4 Protein Causing Pathogenesis in Rotavirus and Its Interaction Studies. <b>2022</b> , 14, 67-79	2
101	Plant Secondary Metabolites: An Introduction of Their Chemistry and Biological Significance with Physicochemical Aspect. <b>2022</b> , 1-45	2
100	Structural exploration of selected C6 and C7-substituted coumarin isomers as selective MAO-B inhibitors.. <b>2022</b> , 1-15	7
99	Chemical Evolution of Natural Product Structure.. <b>2022</b> ,	10
98	Fast fragment- and compound-screening pipeline at the Swiss Light Source.. <b>2022</b> , 78, 328-336	1
97	Fragment-Based Drug Discovery by NMR. Where Are the Successes and Where can It Be Improved?. <b>2022</b> , 9, 834453	3
96	Structure-Based De Novo Design and Docking Studies of 5(S)-Methyl-L-Proline Containing Peptidomimetic Compounds as Dipeptidyl Peptidase-4 Inhibitors.. <b>2021</b> ,	
95	Total Synthesis of Gukulenin B via Sequential Tropolone Functionalizations.. <b>2022</b> ,	2
94	Cytotoxicity, early safety screening, and antimicrobial potential of minor oxime constituents of essential oils and aromatic extracts.. <b>2022</b> , 12, 5319	0
93	High Throughput Screening for Compounds to the Orphan Nuclear Receptor NR2F6.. <b>2022</b> ,	0
92	Puckering the planar landscape of fragments: design and synthesis of a 3D cyclobutane fragment library.. <b>2022</b> ,	0
91	Fragment libraries designed to be functionally diverse recover protein binding information more efficiently than standard structurally diverse libraries.	
90	Stereoselective Palladium-Catalyzed C(sp <sup>3</sup> )–H Mono-Arylation of Piperidines and Tetrahydropyrans with a C(4) Directing Group.	2
89	Critical Assessment of a Structure-Based Screening Campaign for IDO1 Inhibitors: Tips and Pitfalls.. <b>2022</b> , 23,	2
88	Discovery of Cofactor Competitive Inhibitors against the Human Methyltransferase Fibrillarin.. <b>2021</b> , 15,	

87	Selection of Promising Novel Fragment Sized SrtA Noncovalent Inhibitors Based on QSAR and Docking Modeling Studies.. <b>2021</b> , 26,	1
86	Commercial SARS-CoV-2 Targeted, Protease Inhibitor Focused and Protein-Protein Interaction Inhibitor Focused Molecular Libraries for Virtual Screening and Drug Design.. <b>2021</b> , 23,	2
85	Development of Computational Approaches with a Fragment-Based Drug Design Strategy: In Silico Hsp90 Inhibitors Discovery.. <b>2021</b> , 22,	0
84	Table_1.DOCX. <b>2018</b> ,	
83	Data_Sheet_1.csv. <b>2019</b> ,	
82	Data_Sheet_2.pdf. <b>2019</b> ,	
81	Data_Sheet_1.pdf. <b>2019</b> ,	
80	Data_Sheet_2.pdf. <b>2019</b> ,	
79	Data_Sheet_3.xlsx. <b>2019</b> ,	
78	Human Estrogen Receptor Alpha Antagonists, Part 3: 3-D Pharmacophore and 3-D QSAR Guided Brefeldin A Hit-to-Lead Optimization toward New Breast Cancer Suppressants.. <b>2022</b> , 27,	
77	Design of a Potent, Selective, and Brain-Penetrant Inhibitor of Wnt-Deactivating Enzyme Notum by Optimization of a Crystallographic Fragment Hit.. <b>2022</b> ,	2
76	Phenoxy- and Phenylamino-Heterocyclic Quinones: Synthesis and Preliminary Anti-Pancreatic Cancer Activity.. <b>2022</b> , e202101036	0
75	Conditional covalent lethality driven by oncometabolite accumulation.	
74	Comparative Analyses of Medicinal Chemistry and Cheminformatics Filters with Accessible Implementation in Konstanz Information Miner (KNIME). <b>2022</b> , 23, 5727	1
73	Escape from planarity in fragment-based drug discovery: A synthetic strategy analysis of synthetic 3D fragment libraries. <i>Drug Discovery Today</i> , <b>2022</b> ,	8.8 2
72	Identification of natural product inhibitors of de novo lipogenesis enzymes as an anti-cancer strategy: An in silico approach. 1-14	
71	In Silico ADME: Rule-Based Systems. <b>2022</b> , 531-537	
70	Acrylamide fragment inhibitors that induce unprecedented conformational distortions in enterovirus 71 3C and SARS-CoV-2 main protease. <b>2022</b> ,	0

69	Fragment-Based Drug Discovery [The Importance of High Quality Molecule Libraries.	2
68	Maximizing the integration of virtual and experimental screening in hit discovery. 1-12	
67	Rings in Clinical Trials and Drugs: Present and Future.	12
66	Fragment hopping protocol for the design of small-molecule protein-protein interaction inhibitors. <b>2022</b> , 69, 116879	0
65	FGDB: a comprehensive graph database of ligand fragments from the Protein Data Bank. <b>2022</b> , 2022,	0
64	Development of on-DNA vinyl sulfone synthesis for DNA-encoded chemical libraries.	1
63	Recent advances in CADD. <b>2022</b> , 231-281	
62	Forty years of combinatorial technology. <i>Drug Discovery Today</i> , <b>2022</b> ,	8.8 3
61	Fragment-based inhibitor design for SARS-CoV2 main protease.	
60	Development of potent inhibitors by fragment-linking strategies.	
59	Synthesis-Aware Generation of Structural Analogues.	0
58	Principles and Methods of the Pharmaceutical Drug Discovery Process [From Idea over Target to a Development Candidate. <b>2022</b> , 37-61	
57	Probing ligand binding of endothiapepsin by 'temperature-resolved' macromolecular crystallography. <b>2022</b> , 78, 964-974	0
56	Fragment Libraries Designed to Be Functionally Diverse Recover Protein Binding Information More Efficiently Than Standard Structurally Diverse Libraries. <b>2022</b> , 65, 11404-11413	1
55	FastGrow: on-the-fly growing and its application to DYRK1A.	0
54	Towards systematic exploration of chemical space: building the fragment library module in molecular property diagnostic suite.	0
53	3-Chloro-3-methyl-2,6-diarylpiperidin-4-ones as Anti-Cancer Agents: Synthesis, Biological Evaluation, Molecular Docking, and In Silico ADMET Prediction. <b>2022</b> , 12, 1093	0
52	Identification of new anti-cancer agents against CENTERIN: Structure-based virtual screening, AutoDock and binding free energy studies. <b>2022</b> , 1270, 133952	

51	Forces Driving a Magic Bullet to Its Target: Revisiting the Role of Thermodynamics in Drug Design, Development, and Optimization. <b>2022</b> , 12, 1438	0
50	Covalent inhibitors of bacterial peptidoglycan biosynthesis enzyme MurA with chloroacetamide warhead. <b>2022</b> , 243, 114752	1
49	General Strategies for Rational Design and Discovery of Multitarget Drugs. <b>2022</b> , 677-736	0
48	Fragment optimization and elaboration strategies [The discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits.	0
47	Design, synthesis, bio-evaluation, and in silico studies of some N-substituted 6-(chloro/nitro)-1H-benzimidazole derivatives as antimicrobial and anticancer agents. <b>2022</b> , 12, 21621-21646	2
46	Targeting the ubiquitin system by fragment-based drug discovery. 9,	1
45	Unprecedented Combination of Polyketide Natural Product Fragments Identifies the New Hedgehog Signaling Pathway Inhibitor Grisonone.	0
44	Discovery of novel and potent inhibitors against mutational variants of IDH1 protein for glioma therapy: A Fragment-based approach.	0
43	Evaluating the use of absolute binding free energy in the fragment optimisation process. <b>2022</b> , 5,	0
42	Investigation of Molecular Weights and Pharmacokinetic Characteristics of Older and Modern Small Drugs.	1
41	In silico high throughput screening of ZINC database of natural compounds to identify novel histone deacetylase inhibitors.	0
40	X-ray Screening of an Electrophilic Fragment Library and Application toward the Development of a Novel ERK 1/2 Covalent Inhibitor. <b>2022</b> , 65, 12319-12333	0
39	Conditional Covalent Lethality Driven by Oncometabolite Accumulation.	0
38	Exploration of piperidine 3D fragment chemical space: synthesis and 3D shape analysis of fragments derived from 20 regio- and diastereoisomers of methyl substituted pipercolinates.	0
37	Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening. <b>2022</b> , 65, 13714-13735	0
36	Identification of Small Molecules with Improved Potency against Orthopoxviruses from Vaccinia to Smallpox.	0
35	Rosetta <sup>3</sup> Predictive Ability for Low-Affinity Ligand Binding in Fragment-Based Drug Discovery.	0
34	Target-Focused Library Design by Pocket-Applied Computer Vision and Fragment Deep Generative Linking. <b>2022</b> , 65, 13771-13783	1

33	Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery.	1
32	The neural basis of psychedelic action. <b>2022</b> , 25, 1407-1419	1
31	Low-Molecular Weight Small Molecules Can Potently Bind RNA and Affect Oncogenic Pathways in Cells.	0
30	Recent trends in fragment-based anticancer drug design strategies against different targets: A mini-review. <b>2022</b> , 206, 115301	0
29	Bilgisayar Destekli İlaç Keşfi Üzerine Bakışlar. <b>2022</b> , 11, 1-1	0
28	Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery. <b>2022</b> , 15, 1366	2
27	Targeting the phosphoserine phosphatase MtSerB2 for tuberculosis drug discovery, an hybrid knowledge based /fragment based approach. <b>2022</b> , 114935	0
26	Fragment Linker Prediction Using Deep Encoder-Decoder Network for PROTAC Drug Design.	0
25	N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies. <b>2022</b> , 13, 399-420	1
24	Application of the millimeters waves in pharmacy Spectroscopy and imaging. <b>2022</b> ,	0
23	Camel (Camelus spp.) Urine Bioactivity and Metabolome: A Systematic Review of Knowledge Gaps, Advances, and Directions for Future Research. <b>2022</b> , 23, 15024	0
22	Introducing ligand GA, a genetic algorithm molecular tool for automated protein inhibitor design. <b>2022</b> , 12,	0
21	Defining the Potential Targets for Biological Activity of Isoegomaketone Based on Network Pharmacology and Molecular Docking Methods. <b>2022</b> , 12, 2115	0
20	Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model. <b>2022</b> , 129108	0
19	Predicting the Likelihood of Molecules to Act as Modulators of Protein-Protein Interactions.	0
18	FRENCH DISPATCH: GTM-BASED ANALYSIS OF THE CHIMIOTHÈQUE NATIONALE CHEMICAL SPACE.	0
17	Rosetta's Predictive Ability for Low-Affinity Ligand Binding in Fragment-Based Drug Discovery.	0
16	Virtual screening of phytochemicals for drug discovery. <b>2023</b> , 149-179	0

- 15 Drug Discovery in Real Life: An Online Learning Activity for Bioinformatics Students. ○
- 14 Computational approaches in drug discovery and design. **2023**, 53-93 ○
- 13 Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2. **2023**, 79, 304-317 ○
- 12 Design, Synthesis and Cytotoxic Activity of Novel Salicylaldehyde Hydrazones against Leukemia and Breast Cancer. **2023**, 24, 7352 ○
- 11 Current and emerging approaches to noncompetitive AR inhibition. ○
- 10 Chemical Validation of Mycobacterium tuberculosis Phosphopantetheine Adenylyltransferase Using Fragment Linking and CRISPR Interference\*\*. **2023**, 62, ○
- 9 Chemical Validation of Mycobacterium tuberculosis Phosphopantetheine Adenylyltransferase Using Fragment Linking and CRISPR Interference\*\*. **2023**, 135, ○
- 8 Mining the Protein Data Bank to inspire fragment library design. 11, ○
- 7 Computer-aided multi-objective optimization in small molecule discovery. **2023**, 4, 100678 ○
- 6 Green Drug Discovery: Novel Fragment Space from the Biomass-Derived Molecule Dihydrolevoglucosenone (Cyrene™). **2023**, 28, 1777 ○
- 5 E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology. **2023**, 66, 3173-3194 ○
- 4 Novel Arylsulfonylhydrazones as Breast Anticancer Agents Discovered by Quantitative Structure-Activity Relationships. **2023**, 28, 2058 ○
- 3 Synthesis and Characterization of Phenylalanine Amides Active against Mycobacterium abscessus and Other Mycobacteria. **2023**, 66, 5079-5098 ○
- 2 Molecular Filters in Medicinal Chemistry. **2023**, 3, 501-511 ○
- 1 Synthesis of sp<sup>3</sup>-rich heterocyclic frameworks by a divergent synthesis strategy. ○